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1.1 Instability of aspartyl peptides 
 
Peptides and proteins are used as pharmaceuticals for many indications and as diagnostics. 
Advantages of this class of substances are the high activity and high specificity, which correlates with 
relatively low systemic toxicity. The development of recombinant DNA technology allowed the 
industrial production of these substances and dramatically increased the number of peptides and 
proteins on the pharmaceutical market. During the years 2000-2003, a total of 64 biopharmaceuticals 
was approved for human use in North America and Europe, all of them being protein-based drugs [1]. 
This represents over a quarter of all new drug approvals of the same period of time. Moreover, in 2003 
approximately further 500 candidate biopharmaceutical substances were undergoing clinical 
evaluation [1]. Of the proteins thus far approved within the European Union, hormones and cytokines 
represent the largest product categories, additional classes are recombinant blood coagulation 
factors, subunit vaccines and monoclonal antibodies [2]. In addition, many medical agents are 
synthetic peptides and peptidomimetics. 
 
Degradation pathways of peptides and proteins comprise chemical and physical instability (figure 1). 
Chemical instability involves covalent modifications, such as hydrolysis, deamidation, beta-elimination, 
oxidation, enantiomerization and disulfide exchange [3]. In contrast, physical instability refers to 
changes in the higher order structure of the proteins, such as denaturation, aggregation, precipitation 
and adsorption. These processes can lead to loss of structure and physiological activity as well as to 

















Figure 1: Degradation pathways of peptides and proteins 
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Figure 2: Spontaneous isomerization and enantiomerization of L-Asp in peptides. 
 
 
Asparagine (Asn) and aspartic acid (Asp) are among the most unstable amino acids in peptides and 
proteins. Both of them are susceptible to isomerization and enantiomerization and Asn can 
additionally undergo side chain deamidation [3-5]. The initial event in these nonenzymatic reactions is 
the formation of an aminosuccinimidyl (Asu) intermediate (figure 2). The mechanism of succinimide 
formation involves deprotonation of the carboxyl-side backbone amide followed by attack of the 
anionic nitrogen on the side chain carbonyl group. The rate of the succinimide formation depends on 
the primary sequence of the peptide as well as temperature, pH, concentration and ionic strength of 
the solution [3-8]. Neighbouring amino acid residues that allow for chain flexibility and hydrogen-
bonding interactions such as Gly or Ser facilitate the formation of the succinimidyl intermediate. The 
succinimide is subject to spontaneous hydrolysis generating either the native L-aspartyl residue         
(α-Asp) or L-isoaspartyl residue (iso-Asp or β-Asp), in which the peptide backbone chain is connected 
via the β-carboxyl group of the Asp side chain (figure 2). In addition, enantiomerization of the              
L-succinimide to D-succinimide may occur, due to the increased acidity of the succinimidyl α-carbon 
compared to Asp [9]. It has been demonstrated that the rate of Asp enantiomerization in peptides is 
about 105 times faster than that of Asp itself under similar conditions [9, 10]. Successive hydrolysis of 
the D-succinimide leads to the formation of D-Asp and D-iso-Asp (D-β-Asp) residues (figure 2). 
 
Beside being side reactions in solution and solid phase peptide synthesis [11, 12], deamidation, 
isomerization and enantiomerization of Asn and Asp are degradation reactions of natural proteins and 
of peptide and protein drugs [3, 4]. Spontaneous deamidation and isomerization of Asn were found in 
prion proteins [13]. Nabuchi and coworkers studied the stability of human parathyroid hormone under 
acidic and alkaline conditions and found deamidation and isomerization of Asn residues after 
incubation at pH 9 [14]. Fibrillar deposits of β-amyloid proteins containing β-Asp occur in Alzheimer’s 
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disease [15, 16]. Succinimidyl peptides were found in heat stressed solutions of the human amylin 
synthetic analog pramlintide [17]. Enantiomerization and formation of D-Asp peptides could be 
detected by RP-HPLC after incubation of the peptidomimetic klerval [18]. Age-dependent 
accumulation of D-Asp was observed in numerous human tissues, such as tooth dentine, skin, bones 
and ocular lens [19] and has been used to date paleontological material [20]. To minimize the 
accumulation of damaged aspartyl residues in cellular proteins, all mammalians tissues possess the 
protein L-isoaspartyl-O-methyl-transferase (PIMT) [4]. This enzyme uses S-adenosyl-L-methionine to 
methylate L-β-Asp residues but not “normal” L-α-Asp residues. Non-enzymatic deesterification of the 
methylated residues returns them to the succinimide form much more rapidly than in the absence of 
methylation, resulting in the eventual conversion of most of the damaged residues to the L-Asp form. 
However, this protection reaction is less efficient in presence of D-β-Asp residues causing 
accumulation of this form of the amino acid. In addition, proteins containing D-amino acids can 
normally not be metabolized and β-Asp proteins have been found to be immunogenic [21]. 
 
Thus, it is clear that degradation reactions of Asp play a major role in the instability of natural proteins 
as well as peptide and protein pharmaceuticals. They are relatively rapid reactions and were observed 
in a number of compounds. Any of these reactions can occur during production, isolation, purification, 
delivery and storage of peptide and protein drugs. The investigation of the mechanism of these 
degradation reactions is important for understanding the pathogenesis of some diseases as well as for 
optimizing processing and formulation conditions of proteins drugs. 
 
 
1.2 Analytical techniques to investigate aspartic acid degradation 
 
Chemical instability of peptides and proteins has been investigated by different analytical techniques. 
Changes in mass, size, charge, hydrophobicity as well as in UV absorption and fluorescence are used 
to monitor the degradation reactions [22]. 
 
Replacement of an amide by a carboxylic acid as consequence of deamidation causes changes in 
hydrophobicity, polarity and charge. Such changes can be studied by chromatographic methods, such 
as ion-exchange chromatography, reversed phase high performance liquid chromatography (RP-
HPLC), hydrophobic and affinity chromatography as well as by electrophoretic techniques, such as 
isoelectrofocusing, gel electrophoresis and capillary electrophoresis (CE) [4, 22]. Moreover, the mass 
change (∆m = +1 m/z) can be detected by mass spectrometry. 
 
Isomerization of Asp to β-Asp can be observed through blockage of Edman sequencing, because the 
extra carbon in the backbone of the β-Asp residue prevents cyclization to form the anilinothiazolone 
derivative [4]. A direct assay for β-Asp residues involves the use of PIMT for selectively labeling β-Asp 
sites with a 3H- or 14C-methyl group [23]. Tritiated methanol is released from the methylated 
intermediate and can be detected by scintillation counting. To obviate the need for radioactive 
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materials, an alternative method using PIMT analyzes S-adenosyl-L-homocystein, which like methanol 
is produced in stoichiometric amounts by PIMT-dependent methylation of β-Asp residues. UV 
detection is carried out after separation by RP-HPLC or strong cation-exchange HPLC [24-26]. 
Recently Cloos and Fledelius [27] developed immunoassays to determine the level of Asp 
isomerization in collagen. 
 
Enantiomerization of amino acids in peptides was first analyzed after hydrolysis of the peptide in 6 M 
HCl at 100°C for 6h [28]. Aspartic acid was separated from the other amino acids by anion exchange 
chromatography and was analyzed by chiral gas chromatography (GC) or by RP-HPLC after 
derivatisation to give diastereoisomers. This method is time-consuming and, because of the acid-
catalyzed enantiomerization occurring during hydrolysis [29-31], does not provide reproducible results. 
Moreover, the presence of α- and β-Asp linkages in the peptide can not be distinguished by the amino 
acids analysis and has to be established indirectly through the β-Asp resistance to Edman 
degradation. Enantiomerization of an amino acid in peptides results in the formation of diastereomers 
which can be distinguished from one other based on differences in physico-chemical properties. 
Differences in hydrophobicity and polarity can be exploited relatively easily by RP-HPLC. Because 
RP-HPLC is a well-established technique, most of the studies on the degradation of Asp were 
conducted with this method [6, 8, 10, 32]. 
 
 
1.3 Aim of the work 
 
While many studies were published on the factors that influence the formation of the succinimidyl 
intermediate and the isomerization of Asp [3-8, 33], only few investigated Asp enantiomerization in 
peptides. Geiger and Clarke demonstrated extensive enantiomerization of Asp in model hexapeptides 
[10]. Oliyai and Borchardt detected in pH 10 incubations of Asp hexapeptides additional peaks by RP-
HPLC that were assigned as the corresponding D-Asp peptides based on the retention time in relation 
to a standard and by off-line fast atom bombardment mass spectrometry as well as enzymatic 
cleavage studies [7]. D-Asp peptides could be detected by RP-HPLC after incubation of the 
peptidomimetics klerval [18] and of human αA-crystallin [32]. To date only the work of Geiger and 
Clarke reported on the half-life (t1/2) of the hydrolysis and enantiomerization of a model hexapeptide 
[10], but the kinetic of the degradation reaction has not been extensively investigated. Moreover, no 
report on the kinetic of the succinimidyl intermediate has been published. Most of the studies on Asp 
degradation were conducted by RP-HPLC with UV detection, while CE was not tested as analytical 
method. 
 
The present study was conducted in order to investigate the degradation products arising from the 
degradation of aspartyl peptides in acidic and alkaline media, specifically with respect to the 
isomerization and enantiomerization of the Asp residue. The tripeptides Phe-Asp-GlyNH2 and          
Gly-Asp-PheNH2 were used as model compounds in order to compare the influence of the steric 
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hindrance of the Asp-following amino acid on the degradation. For this purpose, the following points 
were evaluated: 
 
1. Synthesis of α/β-D/L-aspartyl peptides as reference substances 
2. Identification of the degradation products arising after incubation of the model tripeptides 
3. Development and validation of an analytical method for the separation of the degradation 
products 
4. Quantification of the degradation products and investigation of the kinetics of the degradation 
reactions 
5. Investigation of the degradation of a succinimidyl model peptide. 
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2. Synthesis of reference substances 
 
 
In order to investigate the degradation of the model aspartyl peptides Phe-Asp-GlyNH2 and Gly-Asp-
PheNH2, pure degradation products were required as reference substances. When available, amino 
acids and dipeptides were purchased from commercial sources. Tripeptides with amidated C-terminal 
end were provided by Dr. Sabbah and were synthesised according to [34]. Tripeptides with a free 
terminal carboxylic function were synthesised by manual solid phase peptide synthesis (SPPS) 
according to standard procedures [35]. 
 
 
2.1 Solid phase peptide synthesis of tripeptides with free terminal carboxyl group 
 
In SPPS a polymer matrix serves simultaneously as solid support for the peptide and as permanent   
C-terminal protecting group. Synthesis starts with the attachment of the first Nα-protected amino acid 
to the linker functionality of the resin. After deprotection of the amino function another activated 
protected amino acid is added. Chain elongation is accomplished by consecutive deprotection and 
coupling steps. Finally, the N-terminal free peptide is cleaved from the resin with concomitant 
deprotection of all side chain functionalities. Advantages of SPPS compared to solution synthesis are: 
(I) the easy and fast washing and filtration steps, (II) the possibility of using reagents in excess thus 
achieving practically quantitative reactions, (III) the minimization of physical losses as the peptide 
remains attached to the support throughout the synthesis and (IV) the possibility of automation. 
 
The two most extensively used protecting combinations in SPPS are the Merrifield strategy (Boc/Bzl-
chemistry) and the Sheppard strategy (Fmoc/tBu-chemistry). In the Merrifield system tert-
butyloxycarbonyl (Boc) is used as Nα-protecting group. This can be quantitatively removed using       
20-50% trifluoroacetic acid (TFA) in dichloromethane (DCM). Benzyl esther derived (Bzl) side-chain 
protecting groups as well as the C-terminal linker to the solid support are removed simultaneously 
employing acids like hydrofluoric acid. Other than in the classical Merrifield system, the Sheppard 
strategy uses 9-fluorenylmethoxycarbonyl (Fmoc) as Nα-protecting group. This group can be rapidly 
and quantitatively removed in alkaline medium in presence of piperidine. Permanent protection of 
side-chain groups is provided by tert-butyl derivatives (tBu), which can be cleaved in acidic medium 
under relatively moderate conditions such as 95% TFA in DCM. Because of its milder reaction 
conditions, the Fmoc strategy is nowadays well established as method of choice in SPPS. 
 
Tripeptides with free terminal carboxylic function were synthesised by Fmoc-based SPPS. A reaction 
scheme is depicted in figure 3. Polystyrene with a 2-chlorotrityl chloride linker was used as resin. The 
Fmoc-protecting group was removed treating the peptidyl-resin with piperidine in dimethylformamide 
(DMF). Amide bond formation involved in situ chemical activation of the carboxy group by N-[(1H- 
 


























































Figure 3: Fmoc-based solid phase peptide synthesis. 
 
 
benzotriazol-1-yl)(dimethylamino)methylene]-N-methylmethanaminium hexafluorophosphate N-oxide 
(HBTU). Cleavage of the products from the resin was achieved with 95% TFA in water. The crude 
peptides were purified by preparative HPLC and their identity was confirmed by mass spectrometry. 
 
 
2.2 Synthesis of succinimidyl peptides 
 
Formation of succinimidyl derivatives is a well known side reaction during both in solution and solid 
phase synthesis of aspartyl peptides [35-37]. Schön and Kisfaludy [38] investigated the formation of 
Asu peptides during removal of the tBu aspartyl side-chain protecting group under different reaction 
conditions. While no cyclization occurred in TFA, over 95% transformation of the protected peptide to 
the Asu peptide was estimated by thin layer chromatography (TLC) after treatment with  3.6 N HCl in 
acetic acid. A scheme of the reaction is depicted in Figure 4. This reaction was used to synthesise the 
succinimidyl peptides Phe-Asu-GlyNH2, Phe-Asu-GlyOH, Gly-Asu-PheNH2 and Gly-Asu-PheOH by














































Figure 4: Synthesis of succinimidyl peptides according to [38]. 
 
 
prolonged incubation of the corresponding aspartyl peptides in HCl/acetic acid. The peptides were 
purified by preparative HPLC and their identity was confirmed by mass spectrometry. 
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3. Incubation of model peptides 
 
 
3.1 Incubation of Phe-Asp-GlyNH2 and Gly-Asp-PheNH2 
 
The purpose of this work was to study the degradation of aspartic acid in peptides with special regard 
to the enantiomerization reaction. The model tripeptides Phe-Asp-GlyNH2 and Gly-Asp-PheNH2 were 
selected in order to compare the influence of steric hindrance of the Asp-following amino acid because 
the initial succinimide formation resulting in the corresponding Asu peptides is known to depend on the 
amino acid sequence [7, 39, 40]. As it has been demonstrated that different degradation products are 
formed depending on the pH of the solution [6, 8, 14], the aspartyl peptides were incubated at two 
different pH values (pH 2 and 10). In addition to isomerization and enantiomerization, further 
degradation reactions can be expected [3, 5]. Deamidation of the C-terminal amide and hydrolysis of 
the peptide amide backbone can occur. A diketopiperazine derivative can be the result of the 
nucleophilic attack of the N-terminal nitrogen on the amide carbonyl between the second and the third 
amino acid [41, 42]. Previous studies have shown that hydrolysis of the peptide backbone is 
predominant at acidic pH while isomerization occurs in alkaline media [6, 14]. Moreover, the 
succinimide is relatively stable at low pH while it is rapidly hydrolysed under neutral and alkaline 
conditions [43, 44]. As the enantiomerization of Asp occurs rather slowly, the incubation was 
performed at 80°C, in order to accelerate the reaction rate. 
 
 
3.2 Incubation of Phe-Asu-GlyOH 
 
After analysis of the incubations of Phe-Asp-GlyNH2 and Gly-Asp-PheNH2 it was clear that various 
reactions contribute to the degradation of the Asp peptides (see chapter 4). In order to investigate the 
enantiomerization reaction independently from other degradation pathways, the model compound 
Phe-Asu-GlyOH was incubated. In this way, the hydrolysis reaction of the Asu ring and the 
consequent formation of α- and β- D/L-Asp products could be selectively studied. After analysis of the 
incubation of Phe-Asp-GlyNH2 it was shown that no ring opening occurs at pH 2 (see paragraph 4.2). 
For this reason, the Asu peptide was incubated only in alkaline medium (pH 10). A preliminary 
experiment was conducted incubating Phe-Asu-GlyOH at a temperature of 80°C. Under these 
conditions the succinimidyl hydrolysis proceeds too fast to allow detection of the degradation of     
Phe-Asu-GlyOH in reasonable time intervals. An incubation temperature of 30°C proved to be 
convenient for the analysis. 
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4. Analysis of degradation products by capillary electrophoresis 
 
 
4.1 Basic principles of peptide analysis by CE 
 
CE is one of the most important techniques for the separation of charged substances. In capillary 
zone electrophoresis (CZE) analytes are separated due to their different mobility in a fused-silica 
capillary filled with an electrolyte solution when an electric field is applied. Equation (1) describes the 
mobility µ of a compound in terms of the physical parameters q (ion charge), η (solution viscosity) and 
r (ion radius): 
 
 
           (1) 





From this equation it is evident that small, highly charged species have high mobilities whereas large, 
minimally charged species have low mobilities. Electrophoretic mobility depends on: (I) properties of 
the analyte itself such as charge, size, shape, (II) properties of the background electrolyte (BGE) such 
as composition, pH, ionic strength, viscosity, temperature and (III) interactions between analytes and 
components of the BGE such as solvatation, dissociation and complex formation. Another parameter 
that influences the migration time is the electroosmotic flow (EOF). The EOF is the bulk flow of liquid 
in the capillary as a consequence of the surface charge on the interior capillary wall. The EOF results 
from the effect of the applied electric field on the solution double-layer at the wall. Changes in the 
chemistry of the capillary wall can affect the velocity of the EOF profoundly and subsequently the 
migration time. Moreover, the EOF causes movement of nearly all species, regardless of charge, in 
the same direction. Thus, cations, neutral species and anions can be detected in a single run since 
they all migrate in one direction. 
 
Differences in the primary structure of peptides cause differences in their properties such as electric 
charge, size, shape and hydrophobicity. Because of its ability to exploit these physico-chemicals 
properties, CE is a convenient, fast and simple analytical technique for the separation of peptides. In 
the last years many application of CE for the separation of peptides have been demonstrated [45-47]. 
In a previous study a CE and a RP-HPLC method for the analysis of Asn peptides were compared. CE 
showed better resolution in shorter analysis time [48]. Moreover, it has been shown that CE can 
separate Asp and β-Asp peptides and the corresponding D-Asp and β-D-Asp diastereomers [49-51]. 
This is due to small differences of the pKa values of both the α-Asp and β-Asp isomers as well as the 
respective diastereomers.  
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4.2 Analysis by CE in achiral buffer 
 
Analysis of the incubation solutions was first performed by CE with UV detection. An aqueous 
phosphate buffer, pH 3.0, was used as background electrolyte (BGE). Using reference substances it 
has been previously shown that the diastereomeric pairs L-Phe-α-L-Asp-GlyNH2/L-Phe-α-D-Asp-
GlyNH2 and L-Phe-β-L-Asp-GlyNH2/L-Phe-β-D-Asp-GlyNH2 can be separated under these conditions 
[50]. Identification of the degradation products was carried out by co-injection of reference substances. 
Potential degradation products that were available as reference substances were injected. Most of the 
degradation products could be identified in this way. Unequivocal identification was performed by on-
line mass spectrometry (MS) detection (see chapter 6). By MS, identification of peaks that were 
previously not assigned by co-injection was achieved. Subsequently, missing reference substances 
were synthesised and co-injected. 
 
As it can be seen in Figure 5, a phosphate buffer, pH 3.0 (CE-System 1, see Materials and Methods, 
paragraph 10.4), was suitable for the analysis of most degradation products in the presence of            
p-aminomethylbenzoic acid (pAMBA) as internal standard. Most of the expected degradation products 
could be identified in the solutions after incubation at pH 2 (see Figures 5A and 5C). Deamidation of 
the C-terminal amide resulted in the free acid form of the tripeptides. The dipeptides Phe-Asp and   
Gly-Asp and the amino acid amides PheNH2 and GlyNH2 were the result of hydrolysis of the peptide 
amide backbone. The Asu peptides could be detected due to their relative stability in acidic solution. 
Peptides containing D-Asp were not observed as the acidity of the succinimidyl α-carbon is not 
sufficiently high to be deprotonated at pH 2, so that no significant epimerization occurred. 
 
As expected, incubations at pH 10 resulted in different degradation patterns compared to pH 2 (see 
Figure 5B and 5D). Cleavage of the backbone amide was not significant while isomerization and 
enantiomerization via the cyclic imide dominated. Deamidation of the C-terminal amide to yield the 
corresponding free acids was observed for all isomers of the tripeptides. The intermediate Asu-
peptides were not detected, due to their low stability under these incubation conditions. 
 
As predicted from the pKa values for the α- and β-Asp free carboxyl groups, the β-Asp peptides 
showed longer migration times than the corresponding α-Asp peptides. In fact, studies on glycin-Asp 
peptides showed that the α-Asp side chain carboxyl group is less acidic than the α-carboxyl group of  
β-Asp, having pKa values of 4.0 and 3.4, respectively [43, 44]. Interestingly, the succinimidyl peptides 
Phe-Asu-GlyOH and Gly-Asu-PheOH migrated slower than the corresponding aspartyl peptides     
Phe-Asp-GlyOH and Gly-Asp-PheOH, despite the fact that the Asp peptides possess two carboxyl 
groups and a higher molecular mass compared to the Asu peptides. This may be explained by an 
increased acidity of the C-terminal carboxyl group due to succinimide formation, so that the 
succinimidyl peptides carry a lower overall positive charge than the Asp peptides. Alternatively, this 
behaviour may be attributed to different hydrodynamic volumes of the compounds. 
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A: Phe-Asp-GlyNH2 pH 2 B: Phe-Asp-GlyNH2 pH 10





























































































































































































































































































Figure 5: Electropherograms of Phe-Asp-GlyNH2 incubated at pH 2 for 12 h (A) and at pH 10 for 24 h (B) and 
Gly-Asp-PheNH2 incubated at pH 2 for 36 h (C) and at pH 10 for 96 h (D). Analysis conditions: 50 mM phosphate 




4.3 Analysis by CE using cyclodextrins 
 
Under the conditions used in CE-system 1 (phosphate buffer, pH 3.0), resolution of all analytes could 
not be achieved. As it can be seen in Figures 5D and 5B, the diastereomeric pair Gly-α-L-Asp-L-
PheNH2 and Gly-α-D-Asp-L-PheNH2 was not resolved and only partial separation of L-Phe-β-L-Asp-
GlyNH2, L-Phe-α-L-Asp-GlyOH and L-Phe-α-D-Asp-GlyOH was possible. An additional selectivity can 
be reached by addition of a chiral compound into the BGE. Cyclodextrins (CDs) are the most popular 
chiral selectors for peptide enantioseparations in CE [52, 53]. CDs are dissolved in the BGE and form 
with analytes host-guest inclusion complexes. These transient diastereomeric complexes differ in their 
physico-chemical properties and can thus be separated. Similarly to enantiomers, diastereomers can 
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form complexes with CDs which have different properties and thus electrophoretic mobilities. 
Consequently, separations that can not be achieved in an achiral medium can be often observed in 
the presence of CDs. 
 
Resolution of Gly-α-L/D-Asp-L-PheNH2 and of L-Phe-β-L-Asp-GlyNH2 and L-Phe-α-L/D-Asp-GlyOH 
was attempted by addition of cyclodextrins to the BGE. Various uncharged and negatively charged 
CDs such as β-CD, methyl-β-CD (M-β-CD), carboxymethyl-β-CD (CM-β-CD), hydroxypropyl-β-CD 
(HP-β-CD) and sulfated-β-CD (S-β-CD) were tested. Concentrations of the selector, pH of the BGE 
and applied voltage were optimized for every sample by injection of reference substances. 
 
 
4.3.1 Analysis of Gly-α-L-Asp-L-PheNH2 and Gly-α-D-Asp-L-PheNH2
 
Figure 6 A shows the separation of the diastereomeric pair Gly-α-L-Asp-L-PheNH2 and Gly-α-D-Asp-
L-PheNH2. Base-line resolution was obtained by the addition of 3 mg/ml S-β-CD to 50 mM phosphate 
buffer, pH 3.0 (CE-System 2, Materials and Methods, paragraph 10.4). The DL diastereomer migrates 
faster than the LL diastereomer which can be of advantage because of the low concentration of the  
DL diastereomer in the incubation solutions. In fact, it is always desirable that the minor substance 
migrates ahead of the principal component, in order to avoid the minor peak to be obscured by 
eventual tailing of the major peak. 
 
A negative consequence of the use of CDs is that the internal standard pAMBA can not be detected. 
This is probably due to the strong interaction between CDs and pAMBA. Negatively charged CDs, 
such as S-β-CD, migrate towards the anode. Substances which interact strongly with the chiral 
selector form negatively charged complexes which migrate towards the anode as well. Because 
analyte detection is carried out at the cathodic end of the capillary, these negatively charged 
complexes can not reach the detection window and can consequently not be detected. Assuming that 
the UV-absorption properties of the diastereomers are identical, the total concentration of Gly-α-L-
Asp-L-PheNH2 and Gly-α-D-Asp-L-PheNH2 were calculated from the area of the peak corresponding 
to both peptides in the analysis in the achiral BGE (CE-system 1). After separation with CDs (CE-
system 2) the peak-area ratio of the two analytes and consequently the amount of Gly-α-L-Asp-L-
PheNH2 and Gly-α-D-Asp-L-PheNH2 were determined. 
 
 
4.3.2 Analysis of L-Phe-β-L-Asp-GlyNH2, L-Phe-α-L-Asp-GlyOH and L-Phe-α-D-Asp-GlyOH 
 
The best separation of L-Phe-β-L-Asp-GlyNH2, L-Phe-α-L-Asp-GlyOH and L-Phe-α-D-Asp-GlyOH was 
achieved by the addition of CM-β-CD to the phosphate buffer. As already discussed for the use of      
S-β-CD, the internal standard was not detected under these conditions. While L-Phe-α-L-Asp-GlyOH  
 


























































































































Figure 6: Separation of the reference substances Gly-α-L-Asp-L-PheNH2 and Gly-α-D-Asp-L-PheNH2 in CE-
System 2 (A) and L-Phe-β-L-Asp-GlyNH2, L-Phe-α-L-Asp-GlyOH and L-Phe-α-D-Asp-GlyOH in CE-System 3 (B). 
Analysis conditions in (A): 50 mM phosphate buffer, pH 3.0, 3 mg/ml S-β-CD. Analysis conditions in (B): 50 mM 





and L-Phe-α-D-Asp-GlyOH are diastereomers, L-Phe-β-L-Asp-GlyNH2 is a different peptide. It 
possesses an additional amide group which absorbs at 215 nm. For this reason, the UV-absorption 
properties of the three substances can not be considered identical and the amount of the analytes 
could not be calculated from the peak-area ratio as discussed for the analysis of Gly-α-L-Asp-L-
PheNH2 and Gly-α-D-Asp-L-PheNH2 (see paragraph 4.3.1). 
 
The addition of an organic solvent such as acetonitrile (ACN) causes a decrease of the viscosity of the 
BGE and a stronger EOF. As a consequence, negatively charged complexes such as those between 
pAMBA and CDs can be transported to the cathode and can be detected after the EOF. Different 
amounts of ACN in the phosphate/CM-β-CD buffer were tested. The addition of 5% acetonitrile (see 
CE-System 3, Materials and Methods) allowed the detection of pAMBA after the EOF with a still 
acceptable resolution of the three peptides (see Figure 6B). 
 
 
4.4 Analysis of the diketopiperazine derivatives cyclo(Phe-Asp) and cyclo(Gly-Asp) 
 
In incubations at pH 2 significant formation of the diketopiperazine derivates cyclo(Phe-Asp) and 
cyclo(Gly-Asp) was observed. These compounds were not detected at first by analysis with CE-
System 1. In fact, at a pH value of 3.0 they are partially negatively charged and migrate after the EOF. 
During CE-MS analysis (see paragraph 6.1), the phosphate buffer had to be replaced by an 
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ammonium formate/acetonitrile buffer. As already discussed in paragraph 4.3.2, the presence of a low 
viscous organic solvent like acetonitrile increases the EOF and allows the detection of negatively 
charged substances, which reach the detection window after the EOF. Separations in the organic 
buffer were faster at the expense of resolution compared to phosphate buffer. A 50 mM formate 
buffer, pH 3.0, containing 10% acetonitrile (CE-System 4, see Materials and Methods, paragraph 
10.4) was used for the analysis of cyclo(Phe-Asp) and cyclo(Gly-Asp). Figure 7A shows the 
separation of the reference substances cyclo(Phe-Asp) and cyclo(Gly-Asp) which migrate after the 
EOF at 11.9 and 12.5 min respectively. 
 
 
4.5 Analysis of the degradation products after incubation of Phe-Asu-GlyOH 
 
In order to investigate the Asp enantiomerization separately from the other degradation reactions, the 
model compound Phe-Asu-GlyOH was incubated at pH 10 at 30°C. A suitable system for the 
separation of the degradation products had to be developed, because Phe-Asu-GlyOH and L-Phe-β-
L-Asp-GlyOH could not be resolved in CE-System 1. Changes in the pH value of the phosphate buffer 
were first tested. Resolution of the critical pair Phe-Asu-GlyOH/L-Phe-β-L-Asp-GlyOH was achieved at 
a pH value of 2.7 or lower. However, under these conditions separation of Phe-Asu-GlyOH and L-Phe-
β-D-Asp-GlyOH was not possible. Partial separation of the three substances was obtained at pH 2.9. 
Because it has been shown that lower capillary temperatures can result in an enhancement of peptide 
resolutions [54], different temperatures were tested. Separation of all substances was achieved in 
phosphate buffer, pH 2.9, at a temperature of 15°C (CE-System 5, Materials and Methods, paragraph 
10.4). Separation of the reference substances is shown in Figure 7B. 
 
 







































































































































Figure 7: Separation of the reference substances cyclo(Phe-Asp) and cyclo(Gly-Asp) in CE-System 4 (A) and of 
the standards corresponding to the degradation products arising after incubation of Phe-Asu-GlyOH at pH 10 in 
CE-System 5 (B). Analysis conditions in (A): 50 mM formic acid, pH 3.0 (ammonia), containing 10% acetonitrile. 
Analysis conditions in (B): 50 mM phosphate buffer, pH 2.9. For details see Materials and Method, paragraph 
10.4. 
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5. Analysis of degradation products by RP-HPLC 
 
 
RP-HPLC is the most commonly used technique for peptide and protein analysis. The partitioning 
separation mechanism of RP-HPLC mainly based on the hydrophobic character of the analytes can 
be considered orthogonal to the separation mechanism of CE based on the charge-to-mass ratio. 
Consequently, differences in the elution and migration order as well as in the resolution of the 
compounds can be expected [51]. Because HPLC is a well-established technique, most of the studies 
on the isomerization and enantiomerization of Asp were conducted with this method [6, 8, 10, 14, 17, 
18, 32]. In this work a gradient RP-HPLC for the analysis of the model aspartyl peptides Phe-Asp-
GlyNH2 and Gly-Asp-PheNH2 and their degradation products was developed as an alternative to CE. 
A direct comparison of the two methods can be interesting to understand advantages and 
disadvantages of both techniques. 
 
 
5.1 Analysis by RP-HPLC in water/acetonitrile 
 
The RP-HPLC method that was developed consisted of a gradient of two eluents. The gradient 
utilising eluent A (0.1% TFA in water) and eluent B (0.1% TFA in water/acetonitrile 5:95 v/v) was 
optimized for each sample. Figure 8A shows the separation of the degradation products of Phe-Asp-
GlyNH2 after incubation at pH 2. This was achieved with a gradient of 7-20% eluent B within 15 min 
(HPLC-System 1a, see Material and Methods, paragraph 10.5). All substances that were detected by 
CE could also be analyzed by RP-HPLC, except for GlyNH2 whose peak was obscured by the tailing 
of the neighbouring peak corresponding to PheOH. Generally, the amidated peptides had shorter 
retention times compared to the corresponding peptides with free carboxyl groups. The succinimidyl 
intermediates Phe-Asu-GlyNH2 and Phe-Asu-GlyOH eluted after the corresponding aspartyl peptides 
because of the higher hydrophobicity of the succinimide moiety compared to Asp. The 
diketopiperazine cyclo(Phe-Asp) had the longest retention time. 
 
The best separation of the degradation products in incubations of Gly-Asp-PheNH2 at pH 2 was 
achieved with a gradient of 1-39% eluent B within 20 min (HPLC-System 1c, see Material and 
Methods, paragraph 10.5). A chromatogram of an incubated sample is depicted in Figure 8C. As 
already observed for Phe-Asp-GlyNH2, the amide eluted before the deamidated peptide and the 
succinimide had the longest retention time. Due to their high polarity, Gly-Asp and cyclo(Gly-Asp) did 
not interact with the stationary phase and eluted in the solvent front. 
 
A representative chromatogram of the degradation products of Phe-Asp-GlyNH2 after incubation at   
pH 10 is shown in Figure 8B. The best separation was achieved with a gradient of 2-13% eluent B 
within 30 min (HPLC-System 1b, see Material and Methods, paragraph 10.5). Except for the 
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A: Phe-Asp-GlyNH2 pH 2 B: Phe-Asp-GlyNH2 pH 10
C: Gly-Asp-PheNH2 pH 2 D: Gly-Asp-PheNH2 pH 10











































































































































































































































































































































































































































































































































Figure 8: Chromatograms of Phe-Asp-GlyNH2 incubated at pH 2 for 24 h (A) and at pH 10 for 48 h (B) and of Gly-
Asp-PheNH2 incubated at pH 2 for 24 h (C) and at pH 10 for 48 h (D). Analysis conditions: mobile phase gradient 
7-20% B within 15 min (A), 2-13% B within 30 min (B), 1-39% B within 20 min (C) and 10-20% B within 15 min (D). 
Eluent A was 0.1% TFA in water and eluent B was 0.1% TFA in water-acetonitrile (5:95 v/v). Flow: 0.2 ml/min. 
Detection at 215 nm. For details see HPLC-System 1a,b,c, and d in Materials and Methods, paragraph 10.5. 
 
 
diastereomeric pair L-Phe-α-L-Asp-GlyOH/L-Phe-α-D-Asp-GlyOH the L-Asp-containing peptides 
eluted faster than the corresponding D-Asp peptides. The isomeric pairs L-Phe-α-L-Asp-GlyNH2/              
L-Phe-β-L-Asp-GlyNH2 and L-Phe-α-D-Asp-GlyOH/L-Phe-β-D-Asp-GlyOH could not be resolved in 
water-acetonitrile mixtures containing TFA. 
 
Separation of the degradation products of Gly-Asp-PheNH2 after incubation at pH 10 was achieved 
with a gradient of 10-20% of eluent B within 15 min (see Figure 8D). In contrast to Phe-Asp-GlyNH2, 
all isomers of Gly-Asp-PheNH2 could be separated. The amide peptides eluted before the deamidated 
compounds and L-Asp containing peptides eluted faster than the corresponding D-Asp peptides. 
5. Analysis of degradation products by RP-HPLC   18
5.2 Analysis by RP-HPLC in phosphate buffer 
 
The isomeric pairs L-Phe-α-L-Asp-GlyNH2/L-Phe-β-L-Asp-GlyNH2 and L-Phe-α-D-Asp-GlyOH/L-Phe-
β-D-Asp-GlyOH could not be resolved in water-acetonitrile mixtures containing TFA. Kaneda et al. [55] 
reported on the separation of isomeric peptides of αA-crystallin using 15 mM phosphate buffer instead 
of aqueous TFA. Subsequently, various isocratic acetonitrile-phosphate buffer mixtures were 
investigated as mobile phases. Partial resolution of L-Phe-α-L-Asp-GlyNH2 and L-Phe-β-L-Asp-
GlyNH2 could be achieved at pH 5.0 with an 85:15 (v/v) mixture phosphate buffer/acetonitrile. Baseline 
resolution of L-Phe-α-D-Asp-GlyOH and L-Phe-β-D-Asp-GlyOH was achieved at pH 4.0 under 
otherwise identical conditions. Figure 9 shows the chromatogram of a Phe-Asp-GlyNH2 sample 
incubated at pH 10 for 48 h and analyzed with an acetonitrile/phosphate buffer, pH 5.0, gradient (2% - 
13% eluent B within 30 min, HPLC-System 2, see Materials and Methods, paragraph 10.5). The 
compounds that were not separated in the water-TFA/acetonitrile gradient could be resolved in the 
phosphate system. However, only partial resolution of the pair L-Phe-α-L-Asp-GlyOH and L-Phe-β-D-
Asp-GlyOH was achieved. At pH 5.0 all peptides with free carboxyl groups eluted faster than the 















































































































Figure 9: Chromatogram of Phe-Asp-GlyNH2 incubated at pH 10 for 48 h and analyzed with HPLC-System 2. 
Analysis conditions: mobile phase gradient 2-13% eluent B within 30 min. Eluent A was 15 mM aqueous 
phosphate, pH 5.0, and eluent B was water-acetonitrile (5:95 v/v). Flow: 0.2 ml/min. Detection at 215 nm. For 
details see Materials and Methods, paragraph 10.5. 
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5.3 Comparison between CE and RP-HPLC 
 
 
RP-HPLC is a well-established and the most frequently used technique for peptide analysis. In 
contrast, CE is not yet established in all laboratories, although in the last years it has been recognized 
as a fast and simple technique for the separation of peptides including stereoisomer analysis [45-47, 
53]. A disadvantage of CE in comparison to HPLC is the strong dependence of the migration time on 
the electroosmotic flow (EOF). Changes in the chemistry of the capillary wall can affect the velocity of 
the EOF profoundly and subsequently the migration time. On the other hand, the EOF is responsible 
for the flat profile of the flow in CE, since the driving force is uniformly distributed along the capillary. 
The flat flow profile is advantageous because it does not directly contribute to the dispersion of the 
solute zones. This is in contrast to that generated by an external pump in HPLC which yields a laminar 
or parabolic flow profile. 
 
Compared to HPLC, method development in CE is more rapid. This involves the use of various BGEs 
(composition of the buffer, pH, additives, temperature), whereas in HPLC the approach normally is to 
use various columns with different stationary phases. As a consequence, the optimization of the 
separation parameters is much faster and cheaper in CE. Furthermore, high separation can be 
achieved in CE. Another advantage of CE is that it requires much smaller sample and reagent 
volumes. Sample consumption is normally in the order of nanoliters in CE and microliters in HPLC. If 
UV detection is applied, CE is generally less sensitive than HPLC. This is due to the short optical 
path-length afforded by the small internal diameter of the capillary. A significant advantage of HPLC is 
the ability to collect fractions of even minor peaks for further characterization. 
 
In incubations at pH 2, all compounds analyzed by RP-HPLC could also be detected by CE except for 
the diketopiperazines cyclo(Phe-Asp) and cyclo(Gly-Asp) which migrated as a anionic compounds 
behind the EOF at pH 3.0. However, these compounds were analysed by switching to a formate 
buffer, pH 3.0, containing 10% acetonitrile (see Figure 7A). On the other hand, Gly-Asp and cyclo(Gly-
Asp) eluted in the solvent front in RP-HPLC and can, therefore, not be reliably analyzed in this system 
(Figure 8C). Moreover, GlyNH2 could not be detected in RP-HPLC because its small peak was 
obscured from the tailing of the neighbouring peak corresponding to PheOH. As pointed out above, 
the analytes had different migration orders compared to the elution orders in RP-HPLC due to the 
different separation mechanisms of both techniques. Interestingly, the deamidated peptides displayed 
longer migration times in CE compared to the C-terminal amidated analogs similarly to RP-HPLC 
using aqueous TFA in the mobile phase where the amides eluted faster than the corresponding 
peptides with a free terminal carboxyl group. 
 
CE analysis of the pH 10 incubations revealed that the diastereomeric pairs Phe-α-L/D-Asp-GlyOH 
and Gly-α-L/D-Asp-PheNH2 could not be resolved using a pH 3.0 run buffer. These pairs could be 
easily resolved by RP-HPLC. However, while all isomers of the Gly-Asp-Phe series could be at least 
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partially separated by RP-HPLC, the α-Asp and β-Asp pairs Phe-α/β-L-Asp-GlyNH2 and Phe-α/β-D-
Asp-GlyOH could not be resolved by RP-HPLC using TFA in water-acetonitrile. As discussed in 
paragraph 5.2, resolution of these compounds was achieved using a phosphate buffer, pH 5.0, 
instead of aqueous TFA in the mobile phase. The use of CDs allowed the separation of those 
substances which could not be resolved by CE in phosphate buffer, pH 3.0.  
 
Concluding, both methods allowed the analysis of most compounds. While two pairs of diastereomers 
could not be separated by CE, RP-HPLC was less efficient resolving peptides containing α-Asp and β-
Asp linkages. Overall, separations that were difficult with one technique proved to be easily achieved 
by the other method illustrating the complementary of HPLC and CE in peptide analysis. 
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6. Identification of degradation products by on-line mass spectrometry 
 
 
In both, CE and RP-HPLC, on-line MS studies were performed in order to confirm the identification of 
the compounds derived from co-injection of reference substances and primarily to identify unknown 
products. Peptide fragments were labelled according to standard rules [56, 57]. A scheme of the 





Coupling of CE with mass spectrometry is a useful tool to characterize peptides. This detection allows 
high selectivity and sensitivity in addition to providing information about the mass and the structure of 
the analytes. For electrospray ionization mass spectrometry (ESI) sheathless interface, liquid junction 
and sheath-liquid interface have been applied [58-61]. A scheme of the coaxial sheat-flow interface is 
shown in Figure 11. The sheath liquid is infused into the ESI source at a constant rate trough the 
coaxial sheath capillary which surrounds the end of the separation capillary. The sheath liquid mixes 




























Figure 10: Schematic representation of the fragments arising from MS analysis of Phe-Asp-GlyNH2 according to 
[56, 57]. The three possible cleavage points of the peptide backbone are called a, b and c when the charge is 
retained at the N-terminal fragment of the peptide and x, y and z when the charge is retained by the C-terminal 
fragment. 



































































Figure 11: Schematic representation of the CE-MS sprayer coaxial sheat-flow interface. 
 
 
electrical contact between the ESI needle and the CE buffer. Recent studies show the robustness and 
competitive sensitivity of the sheath-liquid coupling [62]. The number of applications of CE-MS is still 
limited although a broad range of applications have been demonstrated, including studies of protein 
identification [63, 64], peptide glycosylation [65, 66] and peptide phosphorylation [67]. CE-MS has also 
been employed to study the degradation of peptides [68]. 
 
MS detection in CE was carried out with electrospray ionization. Tandem mass spectrometry was 
performed. Analysis of daughter fragments arising from fragmentation of the [M+H]+-ion gave 
additional information about the structure of the compounds. Because of its low volatility, the aqueous 
phosphate buffer used for the CE-UV analysis is not compatible with MS detection. For this reason, an 
ammonium formate buffer, pH 2.9, containing 10% v/v acetonitrile was used as BGE for CE-MS 
analysis. Due to the increased EOF, separations in this buffer were faster at the expense of resolution 
compared to phosphate buffer. However, the specificity of the MS detection compensated for the loss 
of resolution. 
 
All compounds were detected as [M+H]+-ions, as summarized in Table 1. Representative MS/MS 
spectra of the aspartyl succinimide Phe-Asu-GlyNH2 and Phe-Asu-GlyOH derivatives are shown in 
Figure 12. These were identified from the [M+H]+-ions at m/z 319 (amide) and m/z 320 (acid) 
respectively. Tandem mass spectrometry of these ions yielded predominantly a fragment at m/z 120 
which can be assigned to the a1 fragment [C8H10N]+ resulting from fragmentation of the Phe CH-CO 
bond with retention of the charge in the amino terminal fragment. The fragments at m/z 302 and                
m/z 245 can be assigned to the [M-NH2]+-ion and the [b2-H2O]+-ion, respectively. The peaks at m/z 
341 and m/z 356 in the spectrum of the amide represent the sodium and the potassium adducts of the 
molecular ion. 
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Table 1: [M+H]+-ions of the substances detected after incubations of Phe-Asp-GlyNH2 and Gly-Asp-PheNH2. The 
compounds were observed either from incubations at pH 2 or form incubations at pH 10. 
 
Sequence  Peptide/amino acid [M+H]+  Sequence  Peptide/amino acid [M+H]+
Phe-Asp-Gly Phe-Asp-GlyNH2 337  Gly-Asp-Phe Gly-Asp-PheNH2 337 
 Phe-β-Asp-GlyNH2 337   Gly-β-Asp-PheNH2 337 
 Phe-Asp-GlyOH 338   Gly-Asp-PheOH 338 
 Phe-β-Asp-GlyOH 338   Gly-β-Asp-PheOH 338 
 Phe-Asu-GlyNH2 319   Gly-Asu-PheNH2 319 
 Phe-Asu-GlyOH 320   Gly-Asu-PheOH 320 
 Phe-AspOH 281   Gly-AspOH 191 
 cyclo(Phe-Asp) 263   cyclo(Gly-Asp) 173 
 PheOH 166   PheOH 166 







































































































Figure 12: Electrospray tandem mass spectra of the Phe-Asu-GlyNH2 ion at m/z 319 (A) and of the Phe-Asu-
GlyOH ion at m/z 320 (B). 
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Figure 13: CE-MS traces of incubations of Phe-Asp-GlyNH2 at pH 10 after 24 h. 
 
 
The mass traces of the CE-MS analysis of an incubation of Phe-Asp-GlyNH2 at pH 10 are shown in 
Figure 13. The trace of the ion at m/z 337 (solid line) displayed four peaks corresponding to the          
α-L-Asp peptide, the β-L-Asp peptide and their D-Asp containing diastereomers, which are separated 
under the experimental conditions. The small peak of the trace of the ion at m/z 319 at 12.1 min 
corresponds to the cyclic imide Phe-Asu-GlyNH2 (dotted line). Moreover, four peaks with m/z 338 
could be observed (hatched line). These peaks correspond to the [M+H]+-ions of the free acid forms of 
the tripeptides resulting from deamidation of the terminal GlyNH2 residue. 
 
Tandem mass spectrometry was used to assign the peaks at m/z 337 and m/z 338 to the α-Asp and  
β-Asp series. Mass spectrometric differentiation of α-Asp and β-Asp peptides has been reported by 
Lloyd and coworkers [69], who noticed differences in the loss of CO from aspartyl fragment ions. 
Different relative intensities of b and y fragments of a tryptic heptapeptide of recombinant human stem 
cell factor depending on the presence of α-Asp or β-Asp linkages have been observed [70]. Lehmann 
and coworkers [71] distinguished α-Asp and β-Asp peptides based on the decrease of the b/y ratio of 
b- and y-ions generated by electrospray tandem mass spectrometry. 
 
Figure 14 summarizes the MS/MS spectra of the peaks of the traces at m/z 337 and m/z 338 in the 
analysis of the incubation of Phe-Asp-GlyNH2 at pH 10 represented in Figure 13. Differences in the 
daughter ions depending on the presence of α-Asp and β-Asp linkage can be noticed. Beside the 
ubiquitous b3 fragments at m/z 319 or m/z 320, MS/MS of L-Phe-α-D-Asp-GlyNH2 and L-Phe-α-L-Asp- 
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m/z











































































































































































Figure 14: MS/MS spectra of a CE-MS/MS analysis of an incubation of Phe-Asp-GlyNH2 at pH 10 after 24h, 
under identical conditions as shown in Figure 13. 
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GlyNH2 showed a dominant b2 fragment ion at m/z 263 while the y2 fragment ion at m/z 190 was 
hardly detectable. Low-abundant a1 and a2 fragments at m/z 120 and m/z 235, respectively, could be 
observed. In contrast, the intensity of the y2 fragment ion in the daughter spectra of Phe-β-L-Asp-
GlyNH2 and L-Phe-β-D-Asp-GlyNH2 was similar to that of the b2 fragment ion. In addition, the a1 
fragment [C8H10N]+ at m/z 120 exhibited a higher abundance compared to the peptides containing α-
Asp. Similar results were obtained for the analysis of the corresponding reference substances. 
According to the literature [71], a decrease of the b/y ratio of complimentary b- and y-ions allowed to 
discriminate between α-Asp and β-Asp peptides. 
 
In the same way the α-Asp and β-Asp form of the deamidated peptides could be assigned to the 
peaks observed for the trace of the ion at m/z 338 (Figures 14E, 14F and 14G). All spectra showed a 
b3 fragments at m/z 320 due to the loss of water from the [M+H]+-ion and a a1 fragment at m/z 120 
corresponding to [C8H10N]+. Peptides containing α-Asp displayed a highly abundant b2 fragment ion at 
m/z 263 while the y2 fragment at m/z 191 had very low intensity. In contrast, the spectra of the 
daughter ions of β-Asp containing peptides showed higher abundant y2 fragment ions at m/z 191. In 
addition, the a1 fragments at m/z 120 exhibited a higher relative intensity if compared to the same 
fragment of α-Asp containing peptides. 
 
Similar results were obtained for the incubations of the peptide with inverse amino acid sequence    
Gly-Asp-Phe. Figure 15 depicts the MS/MS spectra of the traces at m/z 337 and m/z 338 in the 
analysis of an incubation of Gly-Asp-PheNH2 at pH 10. Because of the increased EOF in the 
formate/acetonitrile buffer, resolution of the diastereomeric pairs Gly-β-L-Asp-L-PheNH2/Gly-β-D-Asp-
L-PheNH2 and Gly-α-L-Asp-L-PheOH/Gly-α-D-Asp-L-PheOH, which could be separated in phosphate 
buffer, was not achieved. All spectra show intensive y1 fragments at m/z 166 and m/z 165 for the acid 
and the amide, respectively, and the ion at m/z 120 which can be assigned to the fragment [C8H10N]+ 
confirming the presence of Phe in the peptide structure. All spectra show the b3 fragment at m/z 320 
and m/z 319, corresponding to the loss of water. Moreover loss of NH3 was observed for the amide 
structure (fragment at m/z 320). Differences in the fragmentation patterns of Gly-α-Asp-Phe and Gly-
β-Asp-Phe are small if compared to those of the peptides with inverse amino acid sequence. 
Apparently, the tendency to form ions with charge retention at the N-terminus is lower, possibly due to 
the fact that Gly is the N-terminal amino acid. A small relative increase of the b2 fragment ion at            
m/z 173 and of the ion at m/z 274 can be observed in case of the presence of a β-Asp linkage. In the 
spectra of β-Asp containing peptides fragments at m/z 292 and m/z 281 are also detected. The 
fragment at m/z 292 can be attributed to the loss of CO and H2O and CO and NH3 from Gly-α-Asp-
PheOH and Gly-β-Asp-PheNH2, respectively. CE-MS/MS analysis of the corresponding reference 
substances gave similar results. Although not as distinct as for the peptides with N-terminal Phe the 
observed differences in the MS/MS spectra allowed the assignment of the peptides to the α-Asp and 
β-Asp series. 
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Reliable differences in the MS and MS/MS spectra of D-Asp and L-Asp containing peptides could not 
be observed. Thus identification of diastereomers was performed by comparison with synthetic 





Chromatographic separations combined with MS detection are nowadays a standard analytical tool. 
HPLC-MS combines the good efficiency of HPLC with the high sensitivity and selectivity of MS. This 
technique is widely applied in many areas of environmental, pharmaceutical and biochemical analysis 
[72]. Many ionization methods such as electron impact ionization, chemical ionization, ion evaporation 
and fast atom bombardment were used in HPLC-MS [72]. From the wide variety of interfaces 
developed over the years basically only atmospheric pressure ionization techniques (API) are 
nowadays commonly applied [73]. For peptide analysis the most used method of ionization is 
atmospheric pressure electrospray ionization, in which biomolecules are detected after soft ionization 
without significant fragmentation. 
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HPLC-MS experiments were performed with an API single quadrupole MS system with turbo ion spray 
interface. Tandem mass spectrometry was not possible with the present instrument. Nevertheless, 
information about the structure of the analysed compounds could be achieved from the fragmentation 
pattern of the substances. The water/acetonitrile gradient used in RP-HPLC is compatible with MS 
detection and could be used for HPLC-MS analysis. Because of the high flow rate during HPLC 
separation, the flow was split 1:4 before MS detection. 
 
The results obtained by HPLC-MS were similar to those obtained by CE-MS. Figure 16 shows the 
mass spectra of representative substances after RP-HPLC-MS detection. All peptides were detected 
as [M+H]+-ions (see Table 1). As it can be seen in Figures 16A and 16C, the native peptides could be 
easily discriminated from their deamidated forms by the molecular ions at m/z 337 (amides) and      
m/z 338 (carboxylic acid). 
 
In addition, α-Asp and β-Asp peptides could be distinguished by careful analysis of the fragmentation 
pattern as shown for L-Phe-α-L-Asp-GlyNH2 (Figure 16A) and L-Phe-β-L-Asp-GlyNH2 (Figure 16B). 
Besides the [M+H]+- and [M+Na]+-ions the spectra displayed the a1 ion at m/z 120, the y2 ion at m/z 
190 and the b2 ion at m/z 263. The α-Asp peptide exhibited a more intense b2 fragment ion and a low 
abundant y2 fragment ion, while in the case of the β-Asp peptide the b2 ion had lower intensity if 
compared to the y2 fragment ion (Figures 16A and 16B). L-Phe-α-L-Asp-GlyOH and L-Phe-β-L-Asp-
GlyOH (Figures 16C and 16D) displayed a similar fragmentation pattern, with the a1 ion at m/z 120, 
the y2 ion at m/z 191 and the b2 ion at m/z 263. Both the amidated and the deamidated form of the      
α-Asp peptides showed the x2 ion at m/z 217 and the a2 ion at m/z 235, which were not present in the 
spectra of the corresponding β-Asp peptides. In order to confirm these results, reference substances 
were injected. The MS spectra obtained for α-Asp and β-Asp reference peptides were similar to those 
obtained for incubated samples. As already discussed in paragraph 6.1, α-Asp and β-Asp linkages 
could be discriminated from the b/y ratio of complimentary b- and y-ions. 
 
As in CE-MS already observed, differences in the mass spectra of α- and β-Asp peptides derived from 
Gly-Asp-PheNH2 were less pronounced. All spectra showed an intense a1 fragment at m/z 120, an 
intense y1 fragment at m/z 166, and a b3 fragment at m/z 319 or m/z 320 for the native peptide and its 
deamidated form, respectively (Figures 16E and 16F). Less intense ions at m/z 173 and m/z 281 
corresponding to the fragments b2 and y2 respectively could be detected in both α- and β-Asp 
peptides, the b2 fragment having a higher intensity in case of the α linkage. As already discussed for 
CE-MS analysis, the tendency to form ions with charge retention at the N-terminus is lower for the 
Gly-Asp-PheNH2 series. 
 
















































































































































































































































































































Figure 16: Mass spectra of L-Phe-α-L-Asp-GlyNH2 (A), L-Phe-β-L-Asp-GlyNH2 (B), L-Phe-α-L-Asp-GlyOH (C),         
L-Phe-β-L-Asp-GlyOH (D), Gly-α-L-Asp-L-PheOH (E) and Gly-β-L-Asp-L-PheOH (F). (A) and (B) were analyzed 
by injection of reference substances, (C)-(F) were recorded from samples of Phe-Asp-GlyNH2 and Gly-Asp-
PheNH2 after incubation at pH 10. 
 
7. Quantification of degradation products   30
7. Quantification of degradation products 
 
 
In this work a CE and a RP-HPLC method for the analysis of the model tripeptides Phe-Asp-GlyNH2 
and Gly-Asp-PheNH2 and their degradation products were developed. Both methods allowed analysis 
of most degradation products. On the other hand, separation of all degradation products could not be 
achieved in a single running system for both CE and RP-HPLC. In both techniques several 
experimental conditions had to be developed in order to analyse all compounds. 
 
The CE method was chosen for the quantitative analysis of the degradation products. Because of the 
low dispersion of the solute zones, better resolution and efficiency were achieved in CE. Moreover, 
CE allowed analysis in much shorter times, which is of great advantage when many repetitive runs 
have to be performed. In fact, although sample analysis can be performed in approximately 15 min in 
both CE and RP-HPLC (see Figures 5 and 8), HPLC-column equilibration time is much longer than 
CE-capillary rinse time, especially when a gradient is run. Furthermore, analysis of Gly-Asp and 
cyclo(Gly-Asp) was not possible by RP-HPLC, because of the high polarity of these compounds, 
resulting in their elution in the solvent front. 
 
 
7.1 Selection of an internal standard 
 
The use of an internal standard proved to be crucial for reproducibility in CE in order to compensate 
for injection errors and minor fluctuations of the migration times [74-76]. Moreover, an internal 
standard is necessary to avoid errors during sample preparation. A suitable substance is stable during 
incubation at pH 2 and 10 at 80°C, has a chromophore which absorbs at the measuring wavelength 
(215 nm) and does not comigrate with any of the analytes. Tryptophane (Trp), histidine (His),              
3-aminopyridine (3-AP), p-aminobenzoic acid (pABA) and p-aminomethylbenzoic acid (pAMBA) were 
tested as internal standard. While Trp was not stable under alkaline conditions, His, 3-AP and pABA 
comigrated with one of the degradation products. Under the analysis conditions, pAMBA proved to be 
the most convenient compound. 
 
 
7.2 Calibration of reference substances 
 
The assay was validated with respect of linearity. Calibration curves of reference substances were 
recorded from seven different concentrations in a range between 3 and 0.015 µmol/ml (see Materials 
and Methods, paragraph 10.4). The peak area ratio method was used. Each concentration was 
injected three times. For every compound calibration and analysis in the incubation samples were 
carried out under the same conditions (CE-Systems 1-4, see Materials and Methods, paragraph 10.4). 
Good linearity was observed for all substances. Slope of regression and linearity for the reference 
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compounds are listed in Tables 2 and 3. As it can be seen in Table 2, linear relationships with 
regression coefficient, r2, of at least 0.9996 were found for all substances that were calibrated in 
phosphate buffer (CE-System 1). In presence of CM-β-CD (CE-System 3) calibration curves had a 
regression coefficient of at least 0.9949 (Table 3). For calibration of the diketopiperazine derivatives 
cyclo(Phe-Asp) and cylo(Gly-Asp) (CE-System 4) the regression coefficient was at least 0.9986. The 
limit of detection (LOD) was in the range between 0.1 µmol/ml and 0.005 µmol/ml for GlyNH2 and the 
amidated tripeptides, respectively. The limit of quantification (LOQ) of the compound ranged between               
0.3 µmol/ml (GlyNH2)and 0.015 µmol/ml (amidated tripeptides). 
 
 
Table 2: Slope and linearity of the regression curves obtained for CE analysis of reference substances in CE-
System 1 (for details see Materials and Methods, paragraph 10.8). 
 
CE-System 1 (phosphate) 
Compound Slope r2  Compound Slope r2 
L-Phe-α-L-Asp-GlyNH2 1.8080 1.0000 Gly-β-L-Asp-L-PheOH 2.5016 0.9999 
L-Phe-α-D-Asp-GlyNH2 1.6991 0.9999 Gly-β-D-Asp-L-PheOH 2.6071 0.9999 
L-Phe-β-D-Asp-GlyNH2 1.4748 0.9996 Phe-Asu-GlyNH2 2.3288 0.9999 
L-Phe-β-L-Asp-GlyOH 2.1308 0.9999 Phe-Asu-GlyOH 2.5904 0.9999 
L-Phe-β-D-Asp-GlyOH 2.1292 0.9998 Gly-Asu-PheNH2 2.2639 0.9999 
Gly-α-L-Asp-L-PheNH2 2.2737 0.9999 Gly-Asu-PheOH 2.0965 0.9999 
Gly-α-D-Asp-L-PheNH2 2.3092 1.0000 Phe-AspOH 2.6416 0.9999 
Gly-β-L-Asp-L-PheNH2 2.2993 0.9999 Gly-AspOH 0.4067 0.9999 
Gly-β-D-Asp-L-PheNH2 2.2985 0.9999 PheNH2 1.7532 0.9999 
Gly-α-L-Asp-L-PheOH 1.8852 0.9999 PheOH 1.8570 0.9999 
Gly-α-D-Asp-L-PheOH 2.2660 0.9998 
 




Table 3: Slope and linearity of the regression curves obtained for CE analysis of reference substances in CE-
Systems 3 and 4 (for details see Materials and Methods, paragraph 10.8). 
 
CE-System 3 (CM-β-CD) CE-System 4 (formate) 
Compound Slope r2 Compound Slope r2 
L-Phe-β-L-Asp-GlyNH2 2.0804 0.9949 cyclo(Phe-Asp) 2.7411 0.9986 
L-Phe-α-L-Asp-GlyOH 1.5479 0.9981 cyclo(Gly-Asp) 0.5532 0.9992 
L-Phe-α-D-Asp-GlyOH 1.5586 0.9999 
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7.3 Precision 
 
The assay was validated with respect of intraday and interday precision. Two concentrations of each 
compound were analyzed by triplicate injections on the same day (intraday precision) and on three 
consecutive days (interday precision). Acceptable repeatability of the area ratios within one day and 
within three days was observed. The minimal and maximal values of the relative standard deviation 
(RSD) for the lowest and the highest concentration for both intraday and interday precision for all 
compounds are listed in Table 4. The complete data of the ratio corrected area of the individual 
reference substances versus corrected area of the internal standard are summarised in Appendix 
(paragraph 13.1). 
 
The RSD values of the area ratios was 9.34% or lower for calibration in phosphate buffer (CE-
Systems 1 and 5). The RSD values for calibration of the diketopiperazine derivative cyclo(Phe-Asp) 
and cyclo(Gly-Asp) in CE-System 4 (formate buffer containing 10% ACN) were considerably higher. 
This is due to the fact that these negatively charged substances migrate after the EOF and show 
relatively broad peaks, which causes a larger integration error. Moreover, while the RSD values for 
cyclo(Phe-Asp) are good (0.31%-6.07% for intraday precision and 3.69%-12.11% for interday 
precision), the values of cyclo(Gly-Asp) are considerably higher. This is due to the lack of a good 




Table 4: Intraday and interday precision of the peak-area ratios (CPA of the analyte related to CPA of internal 
standard) in CE-System 1, 3 and 4. For details see Materials and Methods, paragraph 10.8. 
 

















3.00 0.03 3.70 0.75 0.18 4.79 
0.015 4.94 8.34 0.06 5.73 6.32 3 
(CM-β-CD) 
 
3.00 4.35 5.67 
 
0.75 1.96 6.76 
0.015 2.83 8.14 0.06 12.11 29.45 4 
(formate) 
 
3.00 6.20 7.74 
 
0.75 3.69 14.00 
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8. Kinetics of degradation reactions 
 
 
8.1 Kinetics of the degradation of Phe-Asp-GlyNH2 and Gly-Asp-PheNH2
 
The model peptides Phe-Asp-GlyNH2 and Gly-Asp-PheNH2 were incubated at pH 2 and 10. Samples 
were withdrawn after 6, 12, 24, 36, 48, 72, 96, 120, 192 and 240 h (for details see Materials and 
Methods, paragraph 10.3). The concentration of the compounds in each sample was calculated using 
equations obtained from calibration curves of reference substances. 
 
 
8.1.1 Incubations at pH 2 
 
Hydrolysis was the main degradation pathway after incubation of Phe-Asp-GlyNH2 at pH 2. A scheme 
of the formation of the degradation products is depicted in Figure 17. Phe-Asp-GlyNH2 can undergo 
hydrolysis of the peptide bond between Asp and GlyNH2 with consequent formation of the dipeptide 
Phe-Asp and GlyNH2. Further deamidation of GlyNH2 yielded GlyOH, which could not be detected by 
UV because of its poor absorption at 215 nm. The dipeptide Phe-AspOH could be further hydrolysed 
to the amino acids PheOH and AspOH. Due to the lack of a chromophore Asp could also not be 
detected. Moreover, nucleophilic attack of the N-terminal nitrogen on the α-carbonyl of Asp in the 
dipeptide Phe-AspOH leaded to the formation of the diketopiperazine derivative cyclo(Phe-Asp). 
 
In addition, Phe-Asp-GlyNH2 can undergo deamidation of the C-terminal amide to yield Phe-Asp-
GlyOH (Figure 17). As already observed for Phe-Asp-GlyNH2, the deamidated peptide was hydrolysed 
to GlyOH and Phe-AspOH, which could be further hydrolysed to PheOH and AspOH. Both the 
amidated and the deamidated form of the tripeptide yielded the corresponding succinimidyl peptides. 
Because the succinimide ring is relatively stable at pH 2, both Phe-Asu-GlyNH2 and Phe-Asu-GlyOH 
could be detected. Deamidation of the terminal end of Phe-Asu-GlyNH2 could also yield Phe-Asu-
GlyOH. 
 
Figure 18 shows the kinetic profiles of Phe-Asp-GlyNH2 and its degradation products after incubation 
at pH 2. The concentration of the compounds in the incubated samples is depicted as a function of 
time. The points represent experimental data and the lines were calculated by non-linear curve fitting 
according to the Bateman equation. The degradation of Phe-Asp-GlyNH2 followed apparent first order 
kinetics with half-life of 7.5 h (Figure 18A). Table 5 summarises the apparent half-lives for the 
formation and the degradation of all substances observed in incubations of Phe-Asp-GlyNH2 at pH 2. 
Phe-AspOH and GlyNH2 were the most abundant degradation products after 24 h of incubation. As 
expected, the formation rate for these two substances were comparable. Formation of Phe-AspOH 
was slightly faster than that of GlyNH2, probably due to the fact that Phe-AspOH can be formed from 
 



















































































hydrolysis of both Phe-Asp-GlyNH2 and Phe-Asp-GlyOH (see Figure 17). After 6 h of incubation 
significant deamidation of the terminal carboxyl group was observed (Figure 18B). However, this 
compound was further degradated very fast to the dipeptide and amino acids. As it can be seen from 
the kinetic profiles for the formation of Phe-Asp-GlyOH, Phe-AspOH and GlyNH2 (Figures 18B, 18E 
and 18G), hydrolysis of the peptide backbone occurred faster than deamidation of the amide of the 
carboxy terminus. Hydrolysis as main degradation pathway was confirmed by the fact that after 240 h 
the main degradation product was PheOH. Due to the fact that PheOH is formed by hydrolysis of   
Phe-AspOH, the kinetic profile of PheOH showed an initial lag phase (Figure 18F). 
 
Similarly to PheOH, cyclo(Phe-Asp) was formed relatively slowly and showed an initial lag phase 
(Figure 18H). Although formation of cyclo(Phe-Asp) can occur in alkaline medium [41, 77], it was not 
noticed in our experiments in incubations at pH 10 where backbone hydrolysis was not observed (see 
paragraph 8.1.2). It can be concluded that this cyclic compound does not directly result from the 
tripeptide but is formed from the dipeptide. Moreover, cyclo(Phe-Asp) was further degradated and its 
concentration decreased after 72 h of incubation. The diketopiperazine ring could be hydrolysed to the 
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Phe-Asp-GlyNH2 pH 2 
 
 








































































































A: L-Phe-α-L-Asp-GlyNH2 B: L-Phe-α-L-Asp-GlyOH
C: Phe-Asu-GlyNH2 D: Phe-Asu-GlyOH
E: Phe-AspOH F: PheOH



















































































Figure 18: Kinetic profiles of Phe-Asp-GlyNH2 and its degradation products after incubation at pH 2. The squares 
represent the experimental data obtained as the means of two incubations, each injected in triplicate. The lines 
were calculated by non-linear curve fitting. 
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Table 5: Apparent half-lives for the formation and degradation of the compounds observed in incubations of           
Phe-Asp-GlyNH2 at pH 2. 
 
Phe-Asp-GlyNH2 pH 2 
 Compound t1/2 formation       
(h) 
t1/2 degradation      
(h) 
 L-Phe-α-L-Asp-GlyNH2 - 7.5 
 L-Phe-α-L-Asp-GlyOH 9.8 3.7 
 Phe-Asu-GlyNH2 6.7 102.1 
 Phe-Asu-GlyOH 32.5 - 
 Phe-AspOH 5.7 69.4 
 PheOH 69.8 - 
 GlyNH2 8.2 196.3 




dipeptide Phe-AspOH which was further degradated to PheOH and AspOH, as mentioned above. 
Decrease of the concentration of cyclo(Phe-Asp) proved that the hydrolysis reaction of the dipeptide to 
give amino acids was faster than its cyclization reaction. Sequence inversion and formation of the 
dipeptide Asp-PheOH was not observed. This is in accordance with literature data on 
diketopiperazines [41]. 
 
The kinetic profiles of the formation of the succinimidyl derivatives Phe-Asu-GlyNH2 and Phe-Asu-
GlyOH are depicted in Figures 18C and 18D. Phe-Asu-GlyOH is relatively stable in acidic medium and 
even after 240 h of incubation significant degradation of this compound was not observed. On the 
other side, the amidated compound Phe-Asu-GlyNH2 reached its highest concentration after 24 h and 
after this time was further degradated. This is probably due to the deamidation of the terminal amide 
with consequent formation of Phe-Asu-GlyOH. 
 
Similar results were obtained for incubations at pH 2 of the peptide with inverse amino acid sequence 
Gly-Asp-PheNH2. Figure 19 depicts a scheme of the formation of the degradation products. As 
already discussed for Phe-Asp-GlyNH2, hydrolysis of the peptide backbone gave the dipeptide          
Gly-AspOH and PheNH2. The latter underwent deamidation to PheOH. Gly-AspOH may be further 
hydrolysed to the amino acids GlyOH and AspOH. Cyclization of the dipeptide Gly-AspOH yielded the 
diketopiperazine cyclo(Gly-Asp). Similar to Phe-Asp-GlyNH2, Gly-Asp-PheNH2 underwent deamidation 
of the C-terminal amide. The deamidated peptide was then further hydrolysed to a dipeptide and 
amino acids. Both Asu peptides Gly-Asu-PheNH2 and Gly-Asu-PheOH were formed and were stable 
under the incubation conditions. 



















































































The kinetic profiles of the degradation of Gly-Asp-PheNH2 and its subsequent products at pH 2 are 
depicted in Figure 20. The degradation reaction of the tripeptide followed apparent first order kinetics 
with a half-life of 18.3 h. The curves corresponding to the degradation products were obtained by non-
linear fitting according to the Bateman equation. Table 6 summarises the apparent half-lives for the 
formation and the degradation of all substances observed in incubations of Gly-Asp-PheNH2 at pH 2. 
Hydrolysis of the peptide backbone was the major degradation pathway. Gly-AspOH reached its 
maximal concentration after 48 h and was further hydrolysed to GlyOH and AspOH, which could not 
be detected by UV. Because the deamidation reaction occurred slower than the hydrolysis reaction, 
the maximal concentration of PheNH2 was reached after 96 h and further degradation of this 
compound proceeded slowly (Figure 20G). The fact that deamidation occured slower than backbone 
hydrolysis was confirmed from the kinetic profile of Gly-Asp-PheOH (Figure 20B), the concentration of 
which increased more slowly than that of the dipeptide Gly-AspOH. Furthermore, the concentration of 
Gly-Asp-PheOH reached a maximum after 24 h and the compound was rapidly further degradated. 
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Gly-Asp-PheNH2 pH 2 
 
 








































































































A: Gly-α-L-Asp-L-PheNH2 B: Gly-α-L-Asp-L-PheOH
C: Gly-Asu-PheNH2 D: Gly-Asu-PheOH
E: Gly-AspOH F: PheOH



































Figure 20: Kinetic profiles of Gly-Asp-PheNH2 and its degradation products after incubation at pH 2. The squares 
represent the experimental data obtained as the means of two incubations, each injected in triplicate. The lines 
were calculated by non-linear curve fitting. 
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Table 6: Apparent half-lives for the formation and degradation of the compounds observed in incubations of       
Gly-Asp-PheNH2 at pH 2. 
 
Gly-Asp-PheNH2 pH 2 
 Compound t1/2 formation     
(h) 
t1/2 degradation       
(h) 
 Gly-α-L-Asp-L-PheNH2 - 18.3 
 Gly-α-L-Asp-L-PheOH 10.2 19.4 
 Gly-Asu-PheNH2 15.6 117.5 
 Gly-Asu-PheOH 44.7 - 
 Gly-AspOH 20.4 46.9 
 PheOH 76.6 - 
 PheNH2 17.7 1050 




Both Asu peptides, Gly-Asu-PheNH2 and Gly-Asu-PheOH, were detected but only small amounts of 
these products were observed. This is probably due to the steric hindrance of Phe as Asp following 
amino acid. The diketopiperazine cyclo(Gly-Asp) could be detected, although its amount was smaller 
that that of cyclo(Phe-Asp) in incubations of Phe-Asp-GlyNH2 at pH 2. As already described for 
cylo(Phe-Asp), a decrease in the concentration of cyclo(Gly-Asp) after 48 h of incubation was 
observed. This is due to the diketopiperazine ring opening with consequent formation of the dipeptide 
Gly-AspOH. Sequence inversion was not noticed. 
 
As expected, degradation proceeded faster for Phe-Asp-GlyNH2 than for Gly-Asp-PheNH2. As it can 
be seen in Tables 5 und 6, the formation of all degradation products observed in incubations of            
Gly-Asp-PheNH2 showed higher half-life values compared to those of Phe-Asp-GlyNH2. This may be 
explained by the steric hindrance of Phe as Asp following amino acid. On the other hand, the 
deamidation rate of the C-terminus was similar for both tripeptides, suggesting that this reaction is not 
influenced by the presence of the Phe side-chain. 
 
 
8.1.2 Incubations at pH 10 
 
In incubations at pH 10 isomerization and enantiomerization via formation of the succinimidyl 
intermediate were observed. The degradation pathways were very similar for both model compounds. 
Figure 21 shows a scheme of the formation of the degradation products after incubation of Phe-Asp-
GlyNH2 at pH 10. The tripeptide underwent isomerization with formation of the corresponding β-Asp 
peptide. Enantiomerization of Asp was observed for both the α-Asp and the β-Asp peptides. 

















































































































Figure 21: Schematic degradation pathway of Phe-Asp-GlyNH2 at pH 10. Brackets show substances that could 
not be detected. 
 
 
Deamidation of the terminal amide of Phe-Asp-GlyNH2 yielded Phe-Asp-GlyOH which can also 
undergo isomerization and enantiomerization via formation of the succinimidyl intermediate. Moreover, 
the α-D-Asp, β-L-Asp and β-D-Asp forms of the amidated peptide may be hydrolysed to the 
corresponding peptides with free terminal carboxyl groups. Due to their low stability in alkaline 
medium, the Asu intermediates could not be detected in the incubations. 
 
Figure 22 shows the kinetic profiles for Phe-Asp-GlyNH2 and its degradation products after incubation 
at pH 10. The concentration of the compounds in the samples is depicted as a function of time. The 
points represent experimental data and the lines were calculated from non-linear fitting according to 
the Bateman equation. The degradation of Phe-Asp-GlyNH2 followed apparent first order kinetics with 
a half-life of 18.3 h. Table 7 summarises the apparent half-lives for the formation and the degradation 
of all substances observed in incubations of Phe-Asp-GlyNH2 at pH 10. After 24 h of incubation the 
main degradation product was L-Phe-α-L-Asp-GlyOH (Figure 22E), which resulted from hydrolysis of 
the terminal amide. This compound reached its highest concentration after 36 h of incubation and it 
was relatively slowly further degradated presumably via the corresponding Asu intermediate to form  
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Phe-Asp-GlyNH2 pH 10 
 
 








































































































A: L-Phe-α-L-Asp-GlyNH2 B: L-Phe-α-D-Asp-GlyNH2
C: L-Phe-β-L-Asp-GlyNH2 D: L-Phe-β-D-Asp-GlyNH2
E: L-Phe-α-L-Asp-GlyOH F: L-Phe-α-D-Asp-GlyOH



































Figure 22: Kinetic profiles of Phe-Asp-GlyNH2 and its degradation products after incubation at pH 10. The 
squares represent the experimental data obtained as the means of two incubations, each injected in triplicate. The 
lines were calculated by non-linear curve fitting. 
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Table 7: Apparent half-lives for the formation and degradation of the compounds observed in incubations of         
Phe-Asp-GlyNH2 at pH 10. 
 
Phe-Asp-GlyNH2 pH 10 
 Compound t1/2 formation       
(h) 
t1/2 degradation       
(h) 
 L-Phe-α-L-Asp-GlyNH2 - 14.1 
 L-Phe-α-D-Asp-GlyNH2 7.4 29.5 
 L-Phe-β-L-Asp-GlyNH2 14.1 18.0 
 L-Phe-β-D-Asp-GlyNH2 23.6 24.5 
 L-Phe-α-L-Asp-GlyOH 12.1 96.5 
 L-Phe-α-D-Asp-GlyOH 16.3 - 
 L-Phe-β-L-Asp-GlyOH 95.2 - 
 L-Phe-β-D-Asp-GlyOH 47.8 - 
 
 
the isomerization and enantiomerization products. After 192 h the main degradation product was        
L-Phe-β-L-Asp-GlyOH (Figure 22G). In accordance to literature data [10, 55], the amount of β-Asp 
containing peptides was higher than that of the corresponding α-Asp peptides. This is evident from 
Figures 22F and 22H for L-Phe-α-D-Asp-GlyOH and L-Phe-β-D-Asp-GlyOH, respectively. 
 
Significant formation of D-Asp containing peptides was also observed. As it can be seen in Figures 
22B and 22D, the peptides Phe-α-D-Asp-GlyNH2 and Phe-β-D-Asp-GlyNH2 were formed relatively fast 
and reached their maximal concentrations after 24 h. These compounds were further degradated by 
hydrolysis of the terminal amide to yield the corresponding peptides with free terminal carboxyl 
groups. As it can be seen in Figures 22F, 22G and 22H, the kinetic profiles of L-Phe-α-D-Asp-GlyOH, 
L-Phe-β-L-Asp-GlyOH and L-Phe-β-D-Asp-GlyOH show an initial lag phase. This is in accordance to 
the fact that this compounds were not directly formed from degradation of the starting peptide but only 
after its deamidation to L-Phe-α-L-Asp-GlyOH or its isomerization and enantiomerization to L-Phe-α-
D-Asp-GlyNH2, L-Phe-β-L-Asp-GlyNH2 and L-Phe-β-D-Asp-GlyNH2 (Figure 21). On the other hand, 
the deamidated peptides were relatively stable under the applied conditions and further significant 
degradation of these substances was not observed up to 240 h of incubation. 
 
The degradation of Gly-Asp-PheNH2 was very similar to that of Phe-Asp-GlyNH2 and is shown in 
Figure 23. The kinetic profiles of the degradation products are depicted in Figure 24. Non-linear fitting 
according to the Bateman equation was performed. The degradation of the model compound Gly-Asp-
PheNH2 followed apparent first order kinetics with a half-life of 26.5 h. Table 8 summarises the 
apparent half-lives for the formation and the degradation of all substances observed in incubations of 
 




















































































































Figure 23: Schematic degradation pathway of Gly-Asp-PheNH2 at pH 10. Brackets show substances that could 
not be detected. 
 
 
Gly-Asp-PheNH2 at pH 10. Isomerization and enantiomerization of Asp proceeded relatively slowly 
and the most abundant degradation product was the deamidated peptide Gly-α-L-Asp-L-PheOH 
(Figure 24E). A significant difference from the degradation of Phe-Asp-GlyNH2 was found in the ratio 
between α-Asp and β-Asp peptides. In incubations of Gly-Asp-Phe-NH2, the amount of α-Asp peptides 
was higher than that of the corresponding β-Asp peptides. This can be seen in Figures 24E and 24G 
for Gly-α-L-Asp-L-PheOH and Gly-β-L-Asp-L-PheOH and in Figures 24F and 24H for Gly-α-D-Asp-L-
PheOH and Gly-β-D-Asp-L-PheOH, respectively. This can be explained by the steric hindrance of the 
Phe side chain, which probably allows the hydrolysis of the Asu intermediates only from one side of 
the ring. The most abundant peptide of the D-Asp series was Gly-α-D-Asp-L-PheOH (Figure 24F). 
The deamidated forms of the peptide were relatively stable up to 240 h incubation, while the amidated 
forms were further degradated to their corresponding peptides with free carboxyl group. 
 
As already discussed for incubations at pH 2, degradation of Gly-Asp-PheNH2 at pH 10 proceeded 
more slowly than that of Phe-Asp-GlyNH2. This can be seen in Tables 7 and 8 from the apparent half-
lives for the formation and the degradation of the compounds observed in incubations of Phe-Asp- 
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Gly-Asp-PheNH2 pH 10 
 
 








































































































A: Gly-α-L-Asp-L-PheNH2 B: Gly-α-D-Asp-L-PheNH2
C: Gly-β-L-Asp-L-PheNH2 D: Gly-β-D-Asp-L-PheNH2
E: Gly-α-L-Asp-L-PheOH F: Gly-α-D-Asp-L-PheOH



































Figure 24: Kinetic profiles of Gly-Asp-PheNH2 and its degradation products after incubation at pH 10. The 
squares represent the experimental data obtained as the means of two incubations, each injected in triplicate. The 
lines were calculated by non-linear curve fitting. 
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Table 8: Apparent half-lives for the formation and degradation of the compounds observed in incubations of          
Gly-Asp-PheNH2 at pH 10. 
 
Gly-Asp-PheNH2 pH 10 
 Compound t1/2 formation     
(h) 
t1/2 degradation      
(h) 
 Gly-α-L-Asp-L-PheNH2 - 26.5 
 Gly-α-D-Asp-L-PheNH2 25.2 30.3 
 Gly-β-L-Asp-L-PheNH2 22.2 41.2 
 Gly-β-D-Asp-L-PheNH2 18.2 83.9 
 Gly-α-L-Asp-L-PheOH 19.7 845.1 
 Gly-α-D-Asp-L-PheOH 51.7 - 
 Gly-β-L-Asp-L-PheOH 66.2 - 




GlyNH2 and Gly-Asp-PheNH2 at pH 10. Isomerization and enantiomerization of Asp proceeded more 
slowly in Gly-Asp-PheNH2 because of the steric hindrance of Phe as Asp-following amino acid. This is 
in accordance with previous studies on the influence of the amino acid sequence on the degradation 
of peptides [7, 39, 40]. Compared to incubations at pH 2, the rate of the degradation at pH 10 was 
slower for both tripeptides. The apparent half-life of the degradation of the Phe-Asp-GlyNH2 was 7.5 h 
at pH 2 and 18.3 at pH 10. For Gly-Asp-PheNH2, the apparent half-life was 14.1 h and 26.5 h at pH 2 
and 10, respectively. 
 
 
8.2 Kinetics of the degradation of Phe-Asu-GlyOH 
 
In order to investigate the enantiomerization reaction independently from other degradation pathways, 
the succinimidyl peptide Phe-Asu-GlyOH was incubated at pH 10. In this way, the enantiomerization 
reaction of the succinimidyl ring and its hydrolysis to give α- and β- D/L-Asp products could be 
selectively studied. A reaction scheme is shown in Figure 25. As already discussed in paragraph 3.2, 
the peptide was incubated at 30°C because at 80°C the succinimidyl hydrolysis proceeds too fast to 
allow detection of the degradation products in reasonable time intervals. Samples were withdrawn 
after 5, 10, 15, 30, 60, 90 and 120 minutes (see Materials and Methods, paragraph 10.3). A 
preliminary experiment showed that after this time an equilibrium was reached and significant further 
degradation did not occur. 
 
 


























































































































































A: 15 min B: 120 min
Figure 26: Electropherograms of the analysis of the incubation of Phe-Asu-GlyOH at pH 10 after 15 min (A) and 
120 min (B). Analysis conditions: 50 mM phosphate buffer, pH 2.9, 15°C (CE-System 5). For details see Materials 
and Methods, paragraph 10.4. 
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Figure 27: Kinetic profiles for the degradation of Phe-Asu-GlyOH at pH 10 (A) and for the formation of its 
degradation products (B). The squares represent the experimental data obtained as the means of two incubations, 
each injected in triplicate. The lines were calculated by non-linear curve fitting. 
 
 
Figure 26 shows the CE-analysis of an incubation of Phe-Asu-GlyOH at pH 10 after 15 min and       
120 min. Separation of the diastereomeric pair L-Phe-α-L-Asp-GlyOH / L-Phe-α-D-Asp-GlyOH was 
achieved in 50 mM phosphate, pH 3.0, containing 16 mg/ml CM-β-CD and 5% acetonitrile (CE-
System 3, see paragraph 4.3.2). At the zero time a single peak corresponding to the Asu peptide was 
found. After a few minutes, four degradation products corresponding to the α-L, β-L, α-D and β-D 
forms of the Asp peptide appeared. After 120 min of incubation the peak of the starting compound had 
completely disappeared and an equilibrium was reached. The kinetic profiles of the compounds are 
depicted in Figure 27. The most abundant degradation product was the β-L-Asp peptide. Moreover, 
significant formation of the α-L-Asp and β-D-Asp peptides was noticed while only small amounts of the 
α-D-Asp peptide were detected. The degradation of the Asu peptide followed apparent first order 
kinetics with a half-life of 15.7 min. The kinetic profiles for the formation of the four degradation 
products could be fitted with an exponential equation of the apparent first order as well. The apparent 
half-lives of these reactions are summarised in Table 9. 
 
The concentration ratio between β-Asp and α-Asp peptides was 3.4:1, which is in accordance with 
literature data [10, 55, 78, 79]. It is interesting to note that the D/L ratio was similar for both the α-Asp 
and the β-Asp containing peptides. The α-D-Asp/α-L-Asp ratio was 0.23:1 and the β-D-Asp/β-L-Asp 
was 0.26:1. Moreover, the apparent half-lives for the formation of both L-Asp peptides were similar 
(13.7 h and 12.6 h for L-Phe-α-L-Asp-GlyOH and L-Phe-β-L-Asp-GlyOH, respectively). For L-Phe-α-
D-Asp-GlyOH and L-Phe-β-D-Asp-GlyOH the the halflives were 28.4 h and 25.4 h. This demonstrates 
that the succinimidyl ring opening is independent of the stereochemistry of the ring. Moreover, it is 
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Table 9: Apparent half-lives for the formation of the compounds observed in incubations of Phe-Asu-GlyOH               
at pH 10. 
 
Phe-Asu-GlyOH pH 10 
 Compound t1/2 formation          
(min) 
t1/2 degradation          
(min) 
 Phe-Asu-GlyOH - 15.7 
 L-Phe-α-L-Asp-GlyOH 13.7 - 
 L-Phe-α-D-Asp-GlyOH 28.4 - 
 L-Phe-β-L-Asp-GlyOH 12.6 - 




 evident that the enantiomerization is much slower than ring opening. This is in accordance with the 
data found by Aylin and coworkers [79] who investigated the hydrolysis reaction of the succinimidyl 
ring by molecular modelling. 




The present study was conducted in order to investigate the degradation products of aspartyl peptides 
in acidic and alkaline media, specifically with respect to the isomerization and enantiomerization of the 
Asp residue. The tripeptides Phe-Asp-GlyNH2 and Gly-Asp-PheNH2 were used as model compounds 
and were incubated at pH 2 and pH 10 at 80°C. 
 
Analysis of the incubated samples was first performed by capillary electrophoresis (CE) with UV 
detection. CE was able to separate most α-Asp and β-Asp peptides and the corresponding α-D-Asp 
and β-D-Asp diastereomers due to small differences of the pKa values of the free carboxyl group of 
both the α-Asp and β-Asp isomers as well as the respective diastereomers. A 50 mM phosphate 
buffer, pH 3.0, was suitable to resolve most of the degradation products. Separations that were not 
possible in this system were achieved by the addition of cyclodextrins to the buffer. 
 
In addition, a RP-HPLC method for the analysis of the degradation products was developed as an 
alternative to the CE method. Most of the compounds could be separated with a gradient of 
acetonitrile in water containing 0.1% trifluoroacetic acid. Resolution of the isomeric pairs L-Phe-α/β-L-
Asp-GlyNH2 and L-Phe-α/β-D-Asp-GlyOH was achieved with a gradient of acetonitrile in phosphate 
buffer, pH 5.0. 
 
Due to the different separation mechanisms, differences in the elution and migration order as well as 
in the resolution of the compounds were observed. Both methods allowed the analysis of most 
compounds. Interestingly, while the two pairs of diastereomers Phe-α-L/D-Asp-GlyOH and Gly-α-L/D-
Asp-PheNH2 could not be separated by CE, HPLC was less efficient resolving peptides containing α-
Asp and β-Asp linkages. Overall, separations that were difficult to achieve with one technique proved 
to be easily accomplished by the other method. 
 
The degradation products were first identified by coinjection of reference substances. Additional on-
line MS detection was performed for both techniques in order to unequivocally identify the 
compounds. All substances were detected as [M+H]+-ions. Analysis of the MS spectra of the peptides 
allowed the assignment of degradation products to the α-Asp or β-Asp series. Differences between 
peptides with an α- and β-linkage were observed in the ratio of the b- and y-ions generated by 
cleavage of the α/β-Asp-X bond and Y-α/β-Asp, respectively. The α-Asp peptide exhibited a more 
intense b2 fragment ion and a low abundant y2 fragment ion, while in the case of the β-Asp peptide the 
b2 ion had lower intensity if compared to the y2 fragment ion. Reliable differences in the spectra of D-
Asp and L-Asp containing peptides could not be observed. Thus, the stereochemistry of the 
degradation products had to be performed by comparison to synthetic peptides with known 
configuration. 
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A CE assay for the analysis of the degradation products arising by incubation of the model peptides by 
pH 2 and 10 was developed and validated with respect of linearity, intraday and interday precision. 
Good linearity and repeatability of the area ratios within one day and within three days were observed 
for all substances. For the tripeptides the limit of detection (LOD) and the limit of quantitation were 
0.005 µmol/ml and 0.015 µmol/ml, respectively. 
 
At pH 2, the major degradation pathway was cleavage of the peptide backbone amide bonds yielding 
dipeptides and amino acids, C-terminal deamidation as well as formation of succinimidyl peptides. 
Hydrolysis of the peptide backbone occurred faster than deamidation, so that only small amounts of 
deamidated tripeptides could be found. The succinimide ring was stable at pH 2 and significant 
degradation of the Asu peptides with free carboxyl groups was not observed. Relatively slow formation 
of diketopiperazine derivatives was found. The diketopiperazines were hydrolysed, but sequence 
inversion was not observed. Amino acids were the most abundant degradation products after 10 days 
of incubation. 
 
In alkaline madium (pH 10) both deamidation of the C-terminal amide as well as isomerization and 
concomitant enantiomerization of Asp were observed for the native amide as well as for the resulting 
deamidated tripeptides. According to a study on hexapeptides by Geiger and Clarke [10], the amount 
of β-Asp containing peptides was higher than that of the corresponding α-Asp peptides for the 
sequence Phe-Asp-Gly. The peptide with the inverse amino acid sequence Gly-Asp-Phe yielded α-
Asp peptides in higher amounts than β-Asp peptides. This was probably due to the steric hindrance of 
Phe, which allowed hydrolysis of the Asu ring only from one side. Significant formation of D-Asp 
containing peptides was found but proceeded relatively slowly. 
 
The degradation of Phe-Asp-GlyNH2 and Gly-Asp-PheNH2 both at pH 2 and 10 followed apparent first 
order kinetics. The formation and degradation of the resulting products could be fitted with a non-linear 
model according to the Bateman equation. 
 
Incubation of Phe-Asu-GlyOH at pH 10 gave additional information on the enantiomerization and on 
the opening reaction of the succinimidyl ring. The degradation of Phe-Asu-GlyOH and the formation of 
the four products L-Phe-α-L-Asp-GlyOH, L-Phe-α-D-Asp-GlyOH, L-Phe-β-L-Asp-GlyOH and L-Phe-β-
D-Asp-GlyOH followed apparent first order kinetics. The ratio between β-Asp and α-Asp peptide 
concentration was 3.4. The α-D-Asp/α-L-Asp ratio was 0.23 and the β-D-Asp/β-L-Asp ratio was 0.26. 
 
Summarising, CE proved to be a powerful technique for the analysis of Asp peptides including the 
isomerization and enantiomerization of the Asp residue. Additional studies will be necessary to explain 
the prevalent formation of α-Asp peptides in model substances with Phe as Asp-following amino acid. 
Moreover, investigations on Asu peptides with different amino acid sequence will be useful to 
understand the influence of the Asp neighbouring amino acid on the enantiomerization. 
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10. Materials and Methods 
 
 
10.1 Fmoc-Solid phase peptide synthesis 
 
200 mg of 2-chlorotrityl chloride resin with a substitution grade of 1.05 mmol/g (corresponding to 0.21 
mmol of the resulting peptide) were allowed to swell in dry DMF. The attachment of the first residue to 
the resin linker was achieved by adding 1.2 equivalents of the Fmoc-protected amino acid dissolved in 
1 ml dry DCM in the presence of 4 equivalents of DIPEA. The mixture was shaken for 3 h at room 
temperature. After this time the resin was washed with DCM/MeOH/DIPEA (17:2:1 v/v/v), DCM and 
DMF. Removal of the N-Fmoc group was achieved by treatment with 5% piperidine in DCM/DMF 
(50:50 v/v) for 10 min followed by 20% piperidine in DMF for 15 min. The resin was then washed 
several times with dry DMF. The coupling of the second amino acid was achieved in the presence of 
HBTU as coupling reagent. 4 equivalents of HBTU were dissolved in 1 ml dry DMF and added to 1.2 
equivalent of the Fmoc-protected amino acid in the presence of 8 equivalents of DIPEA. The resin 
was shaken for 1 h at room temperature. After this time the resin was washed with dry DMF and the 
coupling reaction was repeated as mentioned before. After washing with DMF the resin was treated 
with 20% piperidine in DMF in order to remove the Fmoc-protecting group. The next amino acid was 
coupled following the same procedure described for the second one. After removing the Fmoc-
protecting group from the third amino acid the resin was washed with DMF and DCM. Simultaneous 
cleavage of the peptide from the resin and of the aspartyl side chain protecting group (tBu) was 
achieved treating the resin with 95% TFA in water for 1 h. The resin was filtered and the peptide was 
precipitated in ice-cold diethylether. The peptide was then dissolved in tert-butanol/water (80:20 v/v), 
frozen and lyophilized. 
 
The crude peptides were purified by preparative RP-HPLC and their identity was confirmed by fast 
atom bombardement (FAB) mass spectrometry. 
 
 
Table 10: [M+H]+ of the peptides synthesised by SPPS. Spectra were obtained by FAB mass spectrometry in 
glycerol. 
 
Sequence Peptide [M+H]+  Sequence Peptide [M+H]+
Phe-Asp-Gly L-Phe-L-α-Asp-GlyOH 338  Gly-Asp-Phe Gly-L-α-Asp-L-PheOH 338 
 L-Phe-D-α-Asp-GlyOH 338   Gly-D-α-Asp-L-PheOH 338 
 L-Phe-L-β-Asp-GlyOH 338   Gly-L-β-Asp-L-PheOH 338 
 L-Phe-D-β-Asp-GlyOH 338   Gly-D-β-Asp-L-PheOH 338 
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10.2 Synthesis of succinimidyl peptides 
 
20 mg of aspartyl peptide were dissolved in 0.5 ml of 1.85 M HCl in glacial acetic acid and incubated 
at room temperature for 5 days. After this time over 95% transformation of the Asp peptide to the 
corresponding Asu peptide could be estimated by RP-HPLC. The reaction mixture was purified by 
preparative HPLC and the product was lyophilized. The identity was confirmed by mass spectrometry. 
 
 
Table 11: [M+H]+ of the Asu peptides synthesised according to [38]. Spectra were obtained by FAB mass 
spectrometry in glycerol. 
 
Sequence Peptide [M+H]+  Sequence Peptide [M+H]+
Phe-Asp-Gly Phe-Asu-GlyNH2 319  Gly-Asp-Phe Gly-Asu-PheNH2 319 






A 50 mM phosphate buffer, pH 2.0, was prepared dissolving 6.2 mmol of sodium dihydrogen 
phosphate and 6.3 mmol of phosphoric acid in 250 ml of double distilled, deionized water. The ionic 
strength was adjusted to 0.2 M by addition of 2.56 g sodium chloride. 
A 50 mM borate buffer, pH 10.0, was prepared dissolving 12.5 mmol of sodium tetraborate in 
approximately 180 ml of double distilled deionized water. The solution was titrated to pH 10.0 with 1 N 
sodium hydroxide solution and filled up to 250 ml with water. The ionic strength was adjusted to 0.2 M 
by addition of 0.096 g sodium chloride. 
Solutions of pAMBA were prepared by dissolving 20 mg of pAMBA in 25 ml of buffer at pH 2 and in   
25 ml of buffer at pH 10. These solutions were diluted with buffer to give two stock solutions with a 
final pAMBA concentration of 90 µg/ml. This concentration was chosen because the incubated 
samples were diluted 1:2, so that concentration of pAMBA during analysis was the same as for 
calibration      (30 µg/ml). 
8 mg of peptide were dissolved in 4 ml stock solution of pAMBA. This solution was divided in order to 
obtain two different incubation solutions for every sample. The peptides Phe-Asp-GlyNH2 and Gly-
Asp-PheNH2 were incubated at 80 ± 1°C, while the succinimidyl peptide Phe-Asu-GlyOH was 
incubated at 30 ± 0.5°C. At selected time intervals 100 µl aliquots were withdrawn and added to 200 µl 
of ice-cold water in the case of the incubations at pH 2 and to 200 µl of ice-cold 100 mM phosphoric 
acid in the case of the incubations at pH 10. The samples were thoroughly mixed and stored at -20°C 
until analyzed. Each sample was injected in triplicate and the mean corrected peak-area ratios were 
evaluated. The mean value of the two incubations of the same sample was calculated and the peptide 
concentration was determined using the equations obtained from the respective calibration curves. 
  
10. Materials and Methods   53
10.4 Capillary Electrophoresis with UV detection 
 
Calibration of reference substances and analysis of incubated samples were performed on a P/ACETM 
MDQ Capillary Electrophoresis System (Beckman Coulter, Unterschleißheim, Germany) equipped 
with a diode array detector. Data analysis was carried out with 32 KaratTM Software version 4.0. 
Untreated fused-silica capillaries (BGB Analytik Vertrieb, Schloßböckelheim, Germany) with 50 µm ID 
and       375 µm OD had an effective length of 40 cm and a total length of 50.2 cm. Prior to first use, 
capillaries were rinsed for 15 min with 100 mM sodium hydroxide, 10 min with water, 10 min with 100 
mM H3PO4 and again 10 min with water. Between analyses the capillary was rinsed for 1 min with 100 
mM sodium hydroxide, 1 min with water and 3 min with BGE. Sample solutions were injected at the 
anodic end by hydrodynamic injections at a pressure of 0.5 psi (1 psi = 6894.8 Pa) for 5 s. UV 
detection was carried out at the cathodic end of the capillary at 215 nm. 
 
Buffer, voltage and temperature were optimized for the separation of all degradation products arising 
after incubation of the tripeptides. Five different CE-systems were developed. All buffers were 




This system was used for the analysis of most of the degradation products of the incubated peptides. 
 
BGE:   50 mM phosphate, pH 3.0 
Voltage:  25 KV (35.7 µA) 
Temperature:  20°C 
 
The buffer was prepared by dissolving 50 mmol sodium dihydrogen phosphate in 1000 ml of water 
and titrating the solution to pH 3.0 with 1 M sodium hydroxide. Fresh buffer was prepared every week 




This system was used for the separation of Gly-α-L-Asp-L-PheNH2 and Gly-α-D-Asp-L-PheNH2. 
 
BGE:   50 mM phosphate, pH 3.0, 3 mg/ml S-β-CD 
Voltage:  30 KV (50.1 µA) 
Temperature:  20°C 
 
The buffer was prepared by dissolving 50 mmol of sodium dihydrogen phosphate in 1000 ml of water 
and titrating the solution to pH 3.0 with 1 M sodium hydroxide. 30 mg S-β-CD were dissolved in 10 ml 
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This system was developed for the separation and the analysis of L-Phe-β-L-Asp-GlyNH2, L-Phe-α-L-
Asp-GlyOH and L-Phe-α-D-Asp-GlyOH. 
 
BGE:   50 mM phosphate, pH 3.0, 16 mg/ml CM-β-CD, containing 5% acetonitrile 
Voltage:  25 KV (44.1 µA) 
Temperature:  20°C 
 
The buffer was prepared by dissolving 50 mmol of sodium dihydrogen phosphate in 1000 ml of water 
and titrating the solution to pH 3.0 with 1 M sodium hydroxide. 1.25 g CM-β-CD were dissolved in 50 
ml of the buffer. This solution was titrated to pH 3.0 with 28 ml of 100 mM phosphoric acid (final 
concentration of CM-β-CD = 16 mg/ml). 2.63 ml of acetonitrile were added to this solution. In order to 
avoid evaporation of acetonitrile during analyses, the buffer was covered by a 1 mm thick film of light 




This system was used for the analysis of the diketopiperazine derivatives cyclo(Phe-Asp) and 
cyclo(Gly-Asp). 
 
BGE:   50 mM formic acid, pH 3.0 (ammonia), containing 10% acetonitrile 
Voltage:  30 KV (14.6 µA) 
Temperature:  20°C 
 
The buffer was prepared by dissolving 50 mM of formic acid in 1000 ml of water and titrating the 
solution to pH 3.0 with 25% aqueous ammonia. 10 ml of acetonitrile were added to 90 ml of this 
solution. In order to avoid evaporation of acetonitrile during analyses, the buffer was covered by a        




This system was developed for the separation of Phe-Asu-GlyOH, L-Phe-β-L-Asp-GlyOH and L-Phe-
β-D-Asp-GlyOH after incubation of Phe-Asu-GlyOH at pH 10. 
 
BGE:   50 mM phosphate, pH 2.9 
Voltage:  25 KV (32.5 µA) 
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Temperature:  15°C 
 
The buffer was prepared by dissolving 50 mmol of sodium dihydrogen phosphate in 1000 ml of water 




10.5 RP-HPLC with UV detection 
 
RP-HPLC analyses with UV detection were performed on a Shimadzu system consisting of two LC-
10AD VP pumps, a SPD-10AVP detector, a SCL-10AVP system controller and ClassVP software version 
5.0 (Shimadzu, Kyoto, Japan). The compounds were separated on a Grom-Sil 120 ODS-4 HE column 
(125 mm x 2 mm ID) (Grom Analytik, Rottenburg-Hailfingen, Germany). 10 µl of each sample were 
injected. Analyses were performed at a flow rate of 0.2 ml/min and detection was carried out at 215 
nm. 
 
Eluents and gradients were optimized for every sample. Five different HPLC-systems were developed. 





This system was used for the analysis of most degradation products and consisted of a gradient of 
two eluents: 
 
Eluent A:  0.1% TFA in water 
Eluent B:  0.1% TFA in water-acetonitrile (5:95 v/v) 
 
The gradient was optimized for every sample: 
 
HPLC-System 1a: for the separation of the degradation products arising from the incubation of Phe-
Asp-GlyNH2 at pH 2. 
Gradient:  7-20% eluent B within 15 min 
 
HPLC-System 1b: for the separation of the degradation products arising from the incubation of Phe-
Asp-GlyNH2 at pH 10. 
Gradient:  2-13% eluent B within 30 min 
 
HPLC-System 1c: for the separation of the degradation products arising from the incubation of Gly-
Asp-PheNH2 at pH 2. 
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Gradient:  1-39% eluent B within 20 min 
 
HPLC-System 1d: for the separation of the degradation products arising from the incubation of Gly-
Asp-PheNH2 at pH 10. 




This system was used for the separation of L-Phe-α-L-Asp-GlyNH2/L-Phe-β-L-Asp-GlyNH2 and L-Phe-
α-D-Asp-GlyOH/L-Phe-β-D-Asp-GlyOH 
 
Eluent A:  15 mM aqueous sodium hydrogen phosphate, pH 5.0 
Eluent B:  water-acetonitrile (5:95 v/v) 






CE-MS/MS experiments were performed on a Hewlett Packard 3DCE System (Agilent Technologies, 
Waldbronn, Germany) equipped with an Esquire 3000plus ion-trap mass spectrometer (Bruker 
Daltonik, Bremen, Germany) via the Agilent coaxial sheath-liquid sprayer interface (Agilent 
Technologies, Palo Alto, CA, USA). Post-processing software DataAnalysis version 3.0 and BioTools 
version 2.1 (Bruker Daltonik, Bremen, Germany) have been used. Untreated fused-silica capillaries 
(Polymicro Technologies, Phoenix, AZ, USA) with 50 µm ID and 375 µm OD had a length of 55 cm. 
Sample solutions were injected at the anodic end by hydrodynamic injections at a pressure of 50 mbar 
for 2-4 s. 
Separation and detection conditions were as follows: 
 
BGE:   200 mM formic acid, pH 2.9 (ammonia), containing 10% acetonitrile 
Voltage:  30 KV 
Temperature:  25°C 
ESI-Voltage:  4500 V 
Sheat liquid:  2 µl/min isopropanol/water (1:1) 
Nebulizer gas:  3 psi 
Scan speed:  13000 m/z per second 
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10.7 RP-HPLC-MS 
 
RP-HPLC analyses with MS detection were performed on a HP 1100 series HPLC system (Agilent 
Technologies, Waldbronn, Germany) equipped with an API 165 single quadrupole MS system with 
turbo ion spray interface (Applied Biosystems, Langen, Germany). Data analysis was carried out with 
a HP ChemStation version Rev. A (Agilent Technolgies, Wldbronn, Germany). The compounds were 
separated on a LiChroCART 125-4 LiChrospher 100 RP-18 (5 µm) column (Merck, Darmstadt, 
Germany). 20 µl of sample were injected. Analyses were performed at a flow rate of 1 ml/min, at a 
temperature of 25°C. 
Separation and detection conditions were as follows: 
 
Eluent A:  0.1% TFA in water 
Eluent B:  0.1% TFA in water-acetonitrile (5:95 v/v) 
Gradient:  gradients of systems HPLC-1a,b,c,d 
ESI-Voltage:  5200 V 
Split:   1:4 
Source temperature: 350°C 
Focusing potential: 230 V 
Declustering potential: 50 V 
Entrance potential: -10 V 




10.8 Calibration and Validation 
 
Calibration solutions were prepared in 50 mM phosphate buffer, pH 3.0, containing 30 µmol/ml 
pAMBA as internal standard. For every peptide seven solutions with decreasing concentrations (3.0, 
1.5, 0.75, 0.3, 0.15, 0.06 and 0.015 µmol/ml) were prepared by diluting 15 µmol/ml stock solutions of 
the respective substances. Each sample was injected in triplicate and the mean of the corrected peak-
area ratios (CPA of the analyte related to CPA of internal standard) were calculated. Calibration 
curves were obtained by plotting the analyte concentration on the x-axis versus the peak-area ratio on 
the y-axis. Validation was performed by analyzing two solutions of every peptide (0.75 and 0.06 
µmol/ml) by three repetitive injections on three different days. The complete data for the calibration 
and validation are summarised in Appendix. 
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10.9 Materials, Chemicals and Instrumentation 
 
 
10.9.1 General Instrumentation 
 
Balances  Sartorius PT3100, BP210S, MC5 (Sartorius AG, Göttingen, Germany) 
Drying oven  WTB Binder (Binder GmbH, Tuttlingen, Germany) 
Filters   RC 55 Membrane Filters (Schleicher and Schuell, Dassel, Germany) 
Filtration system Glass Filter Holder 250 ml (Sartorius AG, Göttingen, Germany) 
Hot plate stirrer  IKAMAG® RCT (Renner GmbH, Dannstadt, Germany) 
Lyophylisator  Beta 1-8 (Martin Christ GmbH, Osterode, Germany) 
pH meter  inoLab Level 1 (WTW GmbH, Weilheim, Germany) 
Pipettes  Eppendorf Research 100, 200, 1000 (Eppendorf AG, Hamburg, Germany)  
Rotary evaporator VV 2000 with water bath WB 2000 (Heidolph Instruments GmbH, Kelheim, 
Germany) 
SPPS syringes  5 ml Syringes (AbiMed Analysen-Technik GmbH, Langenfeld, Germany) 
Ultrasonic bath  USR 9 (Merck Eurolab, Darmstadt, Germany) 
Vacuum pump  CVC 2000 (Vacuubrand GmbH, Wertheim, Germany) 
Vortex   Vortex Genie 2TM (Bender and Hobein AG, Zurich, Switzerland) 





Acetonitrile  HPLC gradient grade, Merck KGaA, Darmstadt, Germany 
Amino acids  Bachem AG, Heidelberg, Germany 
CM-β-CD  Wacker-Chemie GmbH, Burghausen, Germany 
DCM   Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
DIPEA   Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
Dipeptides  Bachem AG, Heidelberg, Germany 
DMF   Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
Fmoc Amino Acids Novabiochem, VWR International GmbH, Darmstadt, Germany 
H3PO4 85%  J.T. Baker, Deventer, Holland 
HBTU   Novabiochem, VWR International GmbH, Darmstadt, Germany 
HCOOH  Merck KGaA, Darmstadt, Germany 
Isopropanol  Merck KGaA, Darmstadt, Germany 
NaH2PO4 · H2O  J.T. Baker, Deventer, Holland 
NaOH Pellets  Merck KGaA, Darmstadt, Germany 
NH3 Solution 25% Merck KGaA, Darmstadt, Germany 
pAMBA   Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
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S-β-CD   Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
TFA   Merck KGaA, Darmstadt, Germany 
  




Durch den Fortschritt in der Biotechnologie hat die Zahl der für den Markt zugelassenen biologisch 
aktiven Peptide, Proteine und Peptidomimetika in den letzten Jahren stark zugenommen. Während 
der Verarbeitung, Lagerung und des Transportes unterliegen diese Substanzen chemischen bzw. 
physikalisch-chemischen Abbauprozessen. Diese können sowohl zu Strukturveränderungen und 
somit zum Funktionsverlust der Pharmazeutika als auch zur Entstehung toxischer Abbauprodukte 
führen. Eine der instabilsten Aminosäuren in Peptiden und Proteinen ist die Asparaginsäure (Asp). Sie 
unterliegt im Besonderen der Isomerisierung und Enantiomerisierung über ein Aminosuccinimidyl 
(Asu) -Zwischenprodukt. 
 
Ziel der vorliegenden Arbeit waren Studien zu Abbauprodukten von Aspartylpeptiden in sauren und 
basischen Milieu, besonders aber zu Isomerisierung und Enantiomerisierung der 
Asparaginsäurereste. Die Tripeptide Phe-Asp-GlyNH2 und Gly-Asp-PheNH2 wurden als 
Modellverbindungen verwendet. Sie wurden bei pH 2 und pH 10 über einer Zeitraum von maximal 10 
Tagen bei 80°C inkubiert. 
 
Die inkubierten Proben wurden zuerst mittels Kapillarelektrophorese (CE) mit UV-Detektion analysiert. 
Aufgrund der leicht unterschiedlichen pKa-Werte ihrer freien Carboxylgruppen konnten Peptide mit     
α-Asp und β-Asp von den korrespondierenden Diastereomeren mit α-D-Asp und β-D-Asp getrennt 
werden. Die meisten Abbauprodukte konnten in einem 50 mM Phosphatpuffer, pH 3,0, analysiert 
werden. Trennungen, die in diesem System nicht möglich waren, wurden durch Zugabe von 
Cyclodextrinen zum Puffer erreicht. 
 
Als Alternative zur Analyse der Abbauprodukte wurde zusätzlich eine RP-HPLC-Methode entwickelt. 
Die meisten Verbindungen konnten mit einem Gradienten von Acetonitril in wässriger 
Trifluoressigsäure (0,1% v/v) getrennt werden. Die Isomerenpaare L-Phe-α/β-L-Asp-GlyNH2 und        
L-Phe-α/β-D-Asp-GlyOH wurden mit einem Gradienten von Acetonitril in Phosphatpuffer, pH 5,0, 
getrennt. 
 
RP-HPLC und CE sind aufgrund ihrer unterschiedlichen Trennmechanismen komplementäre 
Techniken. Deshalb wurden Unterschiede in der Reihenfolge der Migration bzw. Elution erwartet. 
Beide Techniken erlaubten die Trennung der meisten Verbindungen. Während mit CE die zwei Paare 
von Diastereomeren Phe-α-L/D-Asp-GlyOH and Gly-α-L/D-Asp-PheNH2 nicht getrennt werden 
konnten, war es mit HPLC problematisch, Peptide mit α-Asp und β-Asp Resten zu trennen. Generell 
waren Trennungen, die sich bei einer der Methoden als schwierig erwiesen, mit der jeweils anderen 
Methode problemlos erreichbar. 
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Die Abbauprodukte der Tripeptide wurden zuerst durch Koinjektion von Referenzsubstanzen 
identifiziert, die durch Festphasen-Peptidsynthese hergestellt wurden. Sowohl für CE als auch für 
HPLC wurde zusätzlich online-MS Detektion durchgeführt, um die Identifizierung über die koinjizierten 
Referenzsubstanzen zu bestätigen und vor allem, um unbekannte Abbauprodukte zu bestimmen. Alle 
Verbindungen konnten als [M+H]+-Ionen detektiert werden. Die Analyse der MS-Spektren der Peptide 
erlaubte die Zuordnung der Abbauprodukte zur α-Asp- und β-Asp-Reihe. Unterschiede zwischen        
α-Asp- und β-Asp Peptiden wurden in dem Verhältnis zwischen den durch Spaltung der α/β-Asp-X 
und Y-α/β-Asp Bindung entstehenden b- und y-Ionen gefunden. Während α-Asp Peptide stärker zu          
b2-Ionen und weniger zu y2-Ionen fragmentierten, zeigten β-Asp Peptiden höhere y2-Ionen 
Intensitäten. Zuverlässige Unterschiede in den Spektren von Peptiden mit D-Asp und L-Asp konnten 
nicht festgestellt werden. Für die Untersuchungen zur Stereochemie der Abbauprodukte musste 
deshalb der Vergleich mit synthetischen Peptiden bekannter Konfiguration durchgeführt werden. 
 
Die Quantifizierung der Abbauprodukte erfolgte mittels CE. Die Methoden wurden mit Hilfe von 
Referenzsubstanzen validiert. Sehr gute Linearität, Wiederholpräzision (Präzision bestimmt mit 
Messungen am gleichen Tag) und laborinterne Vergleichspräzision (Präzision bestimmt mit 
Messungen in drei folgenden Tagen) wurden für alle Verbindungen nachgewiesen. 
 
Inkubation im Sauren (pH2) führte hauptsächlich zur Hydrolyse der Peptidbindungen zu Dipeptiden 
und Aminosäuren, zu C-terminaler Deamidierung und zur Bildung von Succinimidyl-Peptiden. Die 
Spaltung der Peptidkette trat schneller auf als die Deamidierung. Zyklisierung des entstehenden 
Dipeptids führte zur Bildung eines Diketopiperazin-Derivates, das wiederum hydrolysierte. Unter 
diesen Bedingungen war der Succinimidyl-Ring stabil. Nach 10 Tagen Inkubation waren freie 
Aminosäuren die Hauptprodukte des Abbaus. 
 
Bei pH 10 wurde sowohl für die nativen Amide als auch für die entstehenden deamidierten Tripeptide 
Isomerisierung und Enantiomerisierung von Asp beobachtet. Wie schon in der Literatur beschrieben 
[10, 55, 78], war die Menge an β-Aspartyl Peptiden in Inkubationen von Phe-Asp-GlyNH2 größer als 
die an α-Aspartyl Peptiden. Inkubationen des Peptids Gly-Asp-PheNH2 führten zu einer stärkeren 
Bildung von α-Aspartyl Peptiden. Die Ursache dafür ist vermutlich die sterische Hinderung durch den 
Phenylalanin-Rest. Die Entstehung von D-Asp Peptiden konnte in geringem Umfang nachgewiesen 
werden, was darauf hindeutet, dass die Enantiomerisierung langsamer als die Succinimidylringöffnung 
abläuft. 
 
Der Abbau von Phe-Asp-GlyNH2 und Gly-Asp-PheNH2 folgte sowohl bei pH 2 als auch bei pH 10 
einer apparenten Kinetik erster Ordnung. Für die Bildung und den weiteren Abbau der 
Reaktionsprodukte wurden kinetische Profile herstellt. Die erhaltenen Kurven wurden anhand der 
Bateman-Funktion gefittet. Für jedes Abbauprodukt konnte so die Halbwertszeit ermittelt werden. 
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Das Succinimidyl-Peptid Phe-Asu-GlyOH wurde bei pH 10 inkubiert, um die Kinetik der Ringöffnung 
und die damit verbundene Enantiomerisierung von L-Asp-Peptiden getrennt von den anderen 
Abbaureaktionen wie Deamidierung zu untersuchen. Die Bildung von L-Phe-α-L-Asp-GlyOH, L-Phe-α-
D-Asp-GlyOH, L-Phe-β-L-Asp-GlyOH and L-Phe-β-D-Asp-GlyOH folgte einer apparenten Kinetik 
erster Ordnung. Im Gleichgewicht, das sich nach 2 Stunden einstellte, war das Verhältnis zwischen              
β-Aspartyl und α-Aspartyl Peptiden 3,4:1. Das Verhältnis von α-D-Asp/α-L-Asp wurde mit 0,23:1 und 
das von β-D-Asp/β-L-Asp mit 0,26:1 bestimmt. 
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13.1 Calibration of reference substances and validation of the method 
 
13.1.1 Calibration and validation for CE-system 1 and CE-System 5 
 
L-Phe-α-L-Asp-GlyNH2
Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.042 0.001 1.81 - - - 
0.06 0.128 0.002 1.89 0.133 0.004 3.35 
0.15 0.293 0.006 2.14 - - - 
0.3 0.567 0.006 1.03 - - - 
0.75 1.365 0.014 0.99 1.365 0.002 0.18 
1.5 2.709 0.042 1.54 - - - 




Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.047 0.003 6.72 - - - 
0.06 0.130 0.006 4.47 0.126 0.003 2.70 
0.15 0.288 0.005 1.56 - - - 
0.3 0.540 0.005 0.93 - - - 
0.75 1.298 0.013 0.96 1.281 0.016 1.28 
1.5 2.546 0.006 0.23 - - - 




Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.041 0.003 7.17 - - - 
0.06 0.122 0.011 9.1 0.126 0.005 3.65 
0.15 0.273 0.012 4.56 - - - 
0.3 0.494 0.026 5.37 - - - 
0.75 1.179 0.024 2.00 1.167 0.011 0.96 
1.5 2.265 0.019 0.83 - - - 





Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.049 0.002 3.56 - - - 
0.06 0.173 0.002 1.03 0.171 0.004 2.43 
0.15 0.372 0.013 3.44 - - - 
0.3 0.696 0.005 0.70 - - - 
0.75 1.636 0.034 2.05 1.630 0.008 0.50 
1.5 3.177 0.058 1.84 - - - 




Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.052 0.002 3.33 - - - 
0.06 0.180 0.005 2.59 0.1712 0.007 4.22 
0.15 0.390 0.007 1.74 - - - 
0.3 0.716 0.006 0.83 - - - 
0.75 1.707 0.019 1.10 1.664 0.038 2.30 
1.5 3.206 0.026 0.82 - - - 




Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.045 0.003 6.33 - - - 
0.06 0.151 0.001 0.48 0.148 0.003 2.19 
0.15 0.352 0.001 0.31 - - - 
0.3 0.690 0.009 1.25 - - - 
0.75 1.715 0.015 0.90 1.687 0.025 1.47 
1.5 3.459 0.0279 0.80 - - - 







Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.040 0.001 3.23 - - - 
0.06 0.150 0.005 3.27 0.150 0.001 0.72 
0.15 0.365 0.002 0.64 - - - 
0.3 0.704 0.005 0.70 - - - 
0.75 1.744 0.002 0.11 1.741 0.009 0.54 
1.5 3.464 0.031 0.90 - - - 




Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.050 0.0002 0.46 - - - 
0.06 0.160 0.003 2.08 0.160 0.001 0.28 
0.15 0.367 0.001 0.38 - - - 
0.3 0.710 0.010 1.37 - - - 
0.75 1.735 0.006 0.35 1.724 0.018 1.05 
1.5 3.403 0.016 0.48 - - - 




Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.048 0.0003 0.80 - - - 
0.06 0.159 0.005 3.15 0.160 0.001 0.87 
0.15 0.374 0.006 1.49 - - - 
0.3 0.724 0.003 0.45 - - - 
0.75 1.771 0.013 0.72 1.768 0.007 0.37 
1.5 3.484 0.058 1.66 - - - 







Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.040 0.001 3.06 - - - 
0.06 0.134 0.002 1.32 0.132 0.001 1.09 
0.15 0.304 0.002 0.57 - - - 
0.3 0.591 0.017 2.88 - - - 
0.75 1.444 0.019 1.3 1.435 0.015 1.05 
1.5 2.801 0.025 0.91 - - - 




Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.045 0.001 2.53 - - - 
0.06 0.163 0.004 2.69 0.164 0.001 0.82 
0.15 0.379 0.008 2.25 - - - 
0.3 0.734 0.008 1.14 - - - 
0.75 1.779 0.028 1.55 1.782 0.005 0.29 
1.5 3.445 0.077 2.23 - - - 




Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.049 0.001 3.07 - - - 
0.06 0.182 0.002 1.14 0.180 0.002 1.15 
0.15 0.414 0.005 1.31 - - - 
0.3 0.795 0.024 3.03 - - - 
0.75 1.921 0.027 1.39 1.908 0.017 0.92 
1.5 3.723 0.031 0.84 - - - 







Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.042 0.003 7.67 - - - 
0.06 0.176 0.014 7.8 0.176 0.008 4.60 
0.15 0.428 0.008 1.8 - - - 
0.3 0.819 0.020 2.43 - - - 
0.75 2.000 0.045 2.25 1.900 0.091 4.79 
1.5 3.961 0.105 2.66 - - - 




Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.055 0.002 3.08 - - - 
0.06 0.179 0.017 9.59 0.175 0.003 1.79 
0.15 0.396 0.016 4.11 - - - 
0.3 0.749 0.034 4.48 - - - 
0.75 1.787 0.023 1.30 1.795 0.008 0.43 
1.5 3.516 0.007 0.19 - - - 




Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.068 0.005 6.99 - - - 
0.06 0.207 0.010 4.75 0.204 0.002 1.15 
0.15 0.453 0.010 2.17 - - - 
0.3 0.859 0.022 2.56 - - - 
0.75 2.031 0.004 0.18 2.002 0.026 1.31 
1.5 3.944 0.087 2.20 - - - 







Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.038 0.003 6.72 - - - 
0.06 0.140 0.003 2.43 0.139 0.002 1.30 
0.15 0.335 0.002 0.76 - - - 
0.3 0.680 0.014 2.09 - - - 
0.75 1.699 0.049 2.88 1.680 0.017 1.04 
1.5 3.369 0.053 1.57 - - - 




Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.0337 0.002 5.21 - - - 
0.06 0.131 0.001 0.76 0.131 0.001 0.71 
0.15 0.331 0.001 0.31 - - - 
0.3 0.643 0.005 0.75 - - - 
0.75 1.610 0.009 0.56 1.608 0.005 0.34 
1.5 3.184 0.030 0.94 - - - 




Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.066 0.002 2.89 - - - 
0.06 0.210 0.003 1.52 0.201 0.008 3.83 
0.15 0.467 0.007 1.59 - - - 
0.3 0.868 0.005 0.62 - - - 
0.75 2.059 0.006 0.31 1.978 0.076 3.86 
1.5 4.020 0.042 1.04 - - - 







Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 - - - - - - 
0.06 0.024 0.001 4.27 0.023 0.001 5.19 
0.15 0.061 0.004 6.42 - - - 
0.3 0.122 0.003 2.82 - - - 
0.75 0.305 0.004 1.31 0.301 0.004 1.37 
1.5 0.613 0.013 2.14 - - - 




Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.041 0.003 6.75 - - - 
0.06 0.124 0.002 1.39 0.123 0.001 1.15 
0.15 0.282 0.001 0.26 - - - 
0.3 0.542 0.009 1.75 - - - 
0.75 1.334 0.017 1.25 1.311 0.020 1.53 
1.5 2.675 0.046 1.72 - - - 




Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.030 0.003 9.34 - - - 
0.06 0.119 0.004 3.14 0.117 0.002 1.96 
0.15 0.288 0.009 3.30 - - - 
0.3 0.581 0.025 4.26 - - - 
0.75 1.384 0.060 4.36 1.387 0.007 0.52 
1.5 2.774 0.103 3.70 - - - 







Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 - - - - - - 
0.06 - - - - - - 
0.15 - - - - - - 
0.3 0.013 0.001 9.88 - - - 
0.75 0.031 0.001 4.5 0.032 0.001 3.02 
1.5 0.064 0.003 4.11 - - - 









Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 - - - - - - 
0.06 0.054 0.001 2.83 0.060 0.007 12.11 
0.15 0.306 0.019 6.07 - - - 
0.3 0.781 0.012 1.56 - - - 
0.75 2.065 0.006 0.31 2.008 0.074 3.69 
1.5 4.311 0.175 4.06 - - - 




Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 - - - - - - 
0.06 - - - 0.041 0.012 29.45 
0.15 0.063 0.005 8.14 - - - 
0.3 0.117 0.013 11.00 - - - 
0.75 0.357 0.058 16.23 0.309 0.043 14.00 
1.5 0.823 0.015 1.78 - - - 










Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.020 0.002 7.98 - - - 
0.06 0.118 0.007 6.34 0.111 0.007 5.94 
0.15 0.303 0.007 2.19 - - - 
0.3 0.530 0.035 6.54 - - - 
0.75 1.601 0.039 2.46 1.546 0.047 3.06 
1.5 3.045 0.080 2.64 - - - 




Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.019 0.002 8.34 - - - 
0.06 0.097 0.001 0.86 0.091 0.005 5.73 
0.15 0.240 0.006 2.71 - - - 
0.3 0.479 0.007 1.54 - - - 
0.75 1.239 0.030 2.45 1.159 0.078 6.76 
1.5 2.279 0.033 1.46 - - - 




Intraday Precision Interday Precision 
Conc. (µmol/ml) 
CPA SD RSD (%) CPA SD RSD (%) 
0.015 0.023 0.001 4.94 - - - 
0.06 0.105 0.009 8.87 0.098 0.006 6.32 
0.15 0.235 0.011 4.66 - - - 
0.3 0.463 0.010 2.27 - - - 
0.75 1.170 0.080 6.88 1.192 0.023 1.96 
1.5 - - - - - - 









Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 3.405 1.12 1.88 
6 1.940 0.73 1.07 
12 1.134 0.83 0.63 
24 0.378 0.92 0.21 
36 0.142 0.98 0.08 
48 0.057 2.97 0.03 
72 - - - 
96 - - - 
120 - - - 
192 - - - 






Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.212 0.66 0.13 
12 0.207 2.18 0.13 
24 0.113 4.68 0.07 
36 0.052 4.00 0.03 
48 0.021 15.34 0.013 
72 - - - 
96 - - - 
120 - - - 
192 - - - 









Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.212 0.66 0.13 
12 0.207 2.18 0.13 
24 0.113 4.68 0.07 
36 0.052 4.00 0.03 
48 0.021 15.34 0.013 
72 - - - 
96 - - - 
120 - - - 
192 - - - 






Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.048 9.45 0.02 
12 0.102 7.75 0.04 
24 0.171 2.97 0.07 
36 0.215 2.23 0.08 
48 0.247 1.45 0.09 
72 0.301 0.86 0.12 
96 0.341 1.16 0.13 
120 0.365 1.75 0.14 
192 0.393 2.56 0.15 










Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.965 1.07 0.36 
12 1.419 0.85 0.54 
24 1.667 0.84 0.63 
36 1.536 0.18 0.58 
48 1.329 0.6 0.50 
72 0.986 0.94 0.37 
96 0.758 0.71 0.29 
120 0.607 0.89 0.23 
192 0.405 1.66 0.15 






Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.015 11.35 0.37 
12 0.027 7.21 0.65 
24 0.035 6.74 0.83 
36 0.035 4.92 0.84 
48 0.035 3.44 0.84 
72 0.035 4.96 0.83 
96 0.032 5.06 0.75 
120 0.029 6.79 0.68 
192 0.022 10.24 0.53 










Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.015 33.41 0.01 
12 0.060 18.77 0.03 
24 0.193 3.57 0.10 
36 0.319 1.68 0.17 
48 0.429 2.04 0.23 
72 0.626 4.85 0.34 
96 0.787 2.13 0.42 
120 0.903 2.62 0.49 
192 1.191 3.09 0.64 






Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.095 12.7 0.03 
12 0.236 8.97 0.09 
24 0.686 4.70 0.25 
36 0.943 4.54 0.34 
48 1.101 2.55 0.40 
72 1.290 1.82 0.47 
96 1.285 1.43 0.47 
120 1.253 2.26 0.46 
192 0.909 7.62 0.33 









Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 3.469 0.55 1.92 
6 2.519 1.42 1.39 
12 1.892 0.66 1.05 
24 1.042 1.03 0.58 
36 0.597 1.12 0.33 
48 0.357 0.95 0.20 
72 0.145 1.54 0.08 
96 0.070 1.77 0.04 
120 0.033 5.19 0.02 
192 - - - 






Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.394 3.75 0.19 
12 0.602 2.66 0.29 
24 0.750 3.48 0.36 
36 0.663 8.62 0.32 
48 0.515 8.22 0.25 
72 0.258 7.71 0.12 
96 0.121 5.46 0.06 
120 0.059 14.44 0.03 
192 - - - 








Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.103 2.36 0.06 
12 0.143 2.28 0.08 
24 0.157 1.59 0.09 
36 0.133 1.26 0.08 
48 0.106 3.58 0.06 
72 0.064 4.36 0.04 
96 0.038 4.60 0.02 
120 0.017 9.00 0.015 
192 - - - 






Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.083 1.89 0.06 
12 0.131 1.98 0.09 
24 0.193 2.27 0.13 
36 0.207 1.88 0.14 
48 0.199 1.05 0.13 
72 0.147 1.82 0.10 
96 0.099 2.19 0.07 
120 0.061 3.23 0.04 
192 - - - 










Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.517 3.43 0.33 
12 0.799 4.41 0.52 
24 1.245 3.93 0.80 
36 1.364 6.34 0.88 
48 1.328 6.84 0.86 
72 1.155 6.33 0.75 
96 0.995 4.48 0.64 
120 0.892 8.02 0.58 
192 0.563 11.52 0.36 






Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.094 2.41 0.04 
12 0.238 1.56 0.11 
24 0.593 1.31 0.28 
36 0.908 1.55 0.43 
48 1.161 1.01 0.54 
72 1.468 1.42 0.69 
96 1.638 0.75 0.77 
120 1.668 1.07 0.78 
192 1.556 1.74 0.73 











Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.016 27.38 0.01 
12 0.134 6.92 0.09 
24 0.194 6.40 0.12 
36 0.215 10.11 0.14 
48 0.254 6.56 0.16 
72 0.286 5.73 0.18 
96 0.340 5.84 0.22 
120 0.284 11.75 0.18 
192 0.214 21.45 0.14 






Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 - - - 
12 0.050 8.94 0.02 
24 0.155 4.73 0.07 
36 0.280 4.23 0.13 
48 0.396 4.18 0.19 
72 0.619 2.44 0.29 
96 0.818 3.17 0.38 
120 0.928 3.49 0.44 
192 1.125 2.56 0.53 















Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 4.321 1.03 1.90 
6 3.445 0.99 1.51 
12 2.774 0.52 1.22 
24 1.735 0.97 0.76 
36 1.092 0.45 0.48 
48 0.697 1.08 0.31 
72 0.276 2.19 0.12 
96 0.112 1.86 0.05 
120 0.048 2.89 0.02 
192 - - - 






Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.053 4.13 0.02 
12 0.091 2.02 0.04 
24 0.141 2.37 0.06 
36 0.159 4.57 0.07 
48 0.166 2.16 0.07 
72 0.164 1.99 0.07 
96 0.146 2.20 0.06 
120 0.130 2.17 0.06 
192 0.085 3.21 0.04 









Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.167 1.28 0.09 
12 0.224 0.83 0.12 
24 0.248 0.59 0.13 
36 0.207 1.87 0.11 
48 0.163 1.99 0.09 
72 0.079 3.28 0.04 
96 0.036 5.23 0.02 
120 - - - 
192 - - - 






Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
- - 0 - 
- - 0 - 
- - 0 - 
0.030 4.82 0.01 0.030 
0.048 7.22 0.02 0.048 
0.059 2.76 0.03 0.059 
0.072 3.17 0.03 0.072 
0.075 2.78 0.04 0.075 
0.072 1.55 0.03 0.072 
0.056 2.36 0.03 0.056 










Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.066 1.97 0.16 
12 0.118 4.37 0.29 
24 0.182 3.73 0.45 
36 0.201 3.10 0.49 
48 0.204 2.16 0.50 
72 0.175 2.77 0.43 
96 0.143 4.68 0.35 
120 0.106 3.99 0.26 
192 0.038 4.09 0.09 






Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.409 2.45 0.23 
12 0.711 2.36 0.41 
24 1.183 2.14 0.67 
36 1.443 0.96 0.82 
48 1.616 1.44 0.92 
72 1.768 4.05 1.01 
96 1.796 1.05 1.02 
120 1.808 2.14 1.03 
192 1.741 1.17 0.99 











Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 - - - 
12 0.047 2.59 0.02 
24 0.126 1.24 0.07 
36 0.200 3.20 0.11 
48 0.267 2.48 0.14 
72 0.361 2.85 0.19 
96 0.442 3.47 0.24 
120 0.501 1.73 0.27 
192 0.620 2.12 0.33 






Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 - - - 
12 - - - 
24 0.044 48.55 0.08 
36 0.062 22.17 0.11 
48 0.075 33.69 0.14 
72 0.068 27.02 0.12 
96 0.054 35.62 0.10 
120 0.054 23.25 0.10 
192 - - - 















Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 4.241 0.67 1.86 
6 3.714 2.49 1.63 
12 3.251 1.32 1.43 
24 2.428 1.44 1.07 
36 1.850 1.76 0.81 
48 1.412 0.85 0.62 
72 0.815 0.95 0.36 
96 0.473 1.19 0.21 
120 0.282 0.98 0.12 
192 0.063 2.32 0.03 






Time (h) % αDL RSD (%) 
Concentration 
(µmol/ml) 
0 0.00 - - 
6 1.76 10.32 0.03 
12 3.70 2.31 0.05 
24 7.55 1.33 0.08 
36 11.36 3.33 0.09 
48 14.32 2.99 0.09 
72 20.26 3.21 0.07 
96 25.66 4.63 0.05 
120 28.68 4.35 0.04 
192 - - - 








Time (h) % αLL RSD (%) 
Concentration 
(µmol/ml) 
0 100.00 0.00 1.86 
6 98.24 0.18 1.60 
12 96.30 0.09 1.38 
24 92.45 0.11 0.99 
36 88.64 0.43 0.72 
48 85.68 0.50 0.53 
72 79.74 0.81 0.29 
96 74.34 1.60 0.15 
120 71.32 1.75 0.09 
192 - - - 






Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.039 5.43 0.02 
12 0.057 12.09 0.02 
24 0.091 3.24 0.04 
36 0.098 4.74 0.04 
48 0.098 3.20 0.04 
72 0.083 4.14 0.04 
96 0.069 7.76 0.03 
120 0.056 7.31 0.02 
192 - - - 










Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 - - - 
12 - - - 
24 0.042 7.23 0.02 
36 0.058 1.63 0.02 
48 0.066 3.22 0.03 
72 0.070 3.83 0.03 
96 0.065 4.04 0.03 
120 0.058 4.06 0.02 
192 - - - 






Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.024 9.83 0.01 
12 0.108 4.86 0.05 
24 0.286 1.37 0.13 
36 0.470 0.80 0.21 
48 0.628 1.05 0.28 
72 0.875 2.14 0.39 
96 1.015 1.65 0.45 
120 1.090 1.65 0.48 
192 1.113 1.46 0.49 











Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 0.482 2.29 0.26 
12 0.857 2.99 0.45 
24 1.384 3.01 0.73 
36 1.706 3.90 0.90 
48 1.919 2.40 1.02 
72 2.131 1.93 1.13 
96 2.225 3.20 1.18 
120 2.259 2.48 1.20 
192 2.144 1.39 1.14 






Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 - - - 
12 - - - 
24 0.028 7.97 0.01 
36 0.053 12.19 0.02 
48 0.077 12.70 0.03 
72 0.129 11.96 0.05 
96 0.176 10.84 0.07 
120 0.224 13.89 0.09 
192 0.315 10.25 0.13 












Time (h) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
6 - - - 
12 - - - 
24 - - - 
36 0.018 20.70 0.01 
48 0.042 26.02 0.02 
72 0.076 7.42 0.03 
96 0.112 8.00 0.04 
120 0.141 7.31 0.05 
192 0.212 2.95 0.08 












Time (min) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 4.877 1.93 1.88 
5 4.059 4.06 1.57 
10 3.183 2.63 1.23 
15 2.509 1.33 0.97 
30 1.251 1.95 0.48 
60 0.349 9.87 0.13 
90 0.101 12.40 0.04 




Time (min) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
5 - - - 
10 - - - 
15 - - - 
30 0.028 8.40 0.018 
60 0.054 5.45 0.035 
90 0.061 6.63 0.039 




Time (min) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
5 - - - 
10 - - - 
15 - - - 
30 0.185 4.18 0.087 
60 0.315 3.77 0.148 
90 0.379 2.14 0.178 






Time (min) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
5 0.072 11.86 0.05 
10 0.115 3.51 0.07 
15 0.158 3.08 0.10 
30 0.211 3.14 0.14 
60 0.300 9.60 0.19 
90 0.295 6.00 0.19 




Time (min) CPA RSD (%) 
Concentration 
(µmol/ml) 
0 - - - 
5 0.415 6.33 0.195 
10 0.629 4.11 0.295 
15 0.800 3.40 0.375 
30 1.103 3.81 0.518 
60 1.328 1.87 0.623 
90 1.388 2.47 0.651 
120 1.395 2.48 0.655 
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